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THE USE OF MAGNETIC RESONANCE IMAGING AND SPECTROSCOPY TO 
INTERROGATE THE METABOLISM OF BRAIN CANCER AND ASSOCIATED 
IMMUNE CELLS THROUGHOUT THE COURSE OF TUMOR PROGRESSION 
Travis Salzillo, B.S. 
Supervisory Faculty and Chair: Pratip Bhattacharya, Ph.D. 
ABSTRACT 
Rapid diagnosis and therapeutic monitoring of aggressive diseases such as 
glioblastoma (GBM) can improve patient survival by providing physicians the time to 
optimally deliver treatment. This includes early in development, while the tumor is still 
manageable, or following initial therapy, when alternative treatments should be 
considered. The main goal of this project was to determine whether metabolic imaging 
with hyperpolarized magnetic resonance spectroscopy (MRS) could detect changes 
in tumor progression more rapidly than conventional anatomic magnetic resonance 
imaging (MRI) in patient-derived GBM murine models. To comprehensively capture 
the dynamic nature of cancer metabolism, in vivo pyruvate-to-lactate conversion with 
hyperpolarized MRI, ex vivo metabolite pool size with nuclear magnetic resonance 
(NMR) spectroscopy, and ex vivo protein expression with immunohistochemistry (IHC) 
were measured at several time-points throughout tumor progression (tumor 
development, regression, and recurrence).  
Hyperpolarized MRS was capable of detecting significant changes in pyruvate-
to-lactate conversion throughout tumor progression, whereas tumor volume measured 
with anatomic MRI was not significantly altered during regression or recurrence. This 
was accompanied by alterations in amino acid and phospholipid lipid metabolism and 
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MCT1 expression. It is discussed how hyperpolarized MRS can help address clinical 
challenges such as identifying malignant disease prior to aggressive growth, 
differentiating pseudoprogression from true progression, quantifying treatment 
response, and predicting relapse. The individual evolution of these metabolic assays 
as well as their correlations with one another provides context for further academic 
research.  
In addition to investigating GBM tumor progression, preliminary and supporting 
metabolic profiling data acquired with NMR spectroscopy is presented in the context 
of immunometabolism. Specifically, metabolic events associated with the licensing 
process of natural killer cells as well as macrophage polarization are analyzed. 
Collectively, this work demonstrates the value of interrogating the metabolism of GBM 
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State of Glioblastoma Patient Care 
In 2020, an estimated 87,240 new cases of primary brain and other central 
nervous system (CNS) tumors will be diagnosed in the United States with 25,800 
expected to be malignant 1. WHO grade IV glioblastoma (GBM) is the most common 
malignant brain tumor in adults representing 48.3% of the cases as well as the most 
deadly with 5-year survival rates of merely 6.8%. Despite standard-of-care treatment 
with surgery, radiotherapy, and temozolomide chemotherapy, prevailing therapies 
remain palliative, and tumors are almost always recurrent and lead to median survival 
times of approximately 15 months 2. The only other FDA-approved treatments for 
primary or recurrent GBM are carmustine wafers 3,4, bevacizumab 5, lomustine 6, and 
tumor treating fields device 7, which have shown modest improvements in overall 
survival. A number of novel treatments such as epigenetic, viral, and gene therapies 
along with small molecule chemotherapeutics and immunotherapies are being studied 
extensively, and several clinical trials have been initiated 8; however, little to no impact 
on survival has been reported as factors such as relatively average mutational load, 
tumor heterogeneity, and molecular filtration by the blood-brain barrier challenge drug 
development for this disease 9. This failure to make major inroads points to the need 






Conventional Medical Imaging  
Imaging has been used to inform anatomic-based intervention by determining 
the extent of involvement of the tumor, its proximity to functional regions, and 
monitoring recurrence. The primary modality for imaging GBM is magnetic resonance 
imaging (MRI) due to its exquisite soft tissue contrast 10. Conventional MRI measures 
1H signal originating from tissue in the body when excited in a magnetic field. The 
primary source of this signal is water, but lipids and other 1H-containing molecules 
also contribute to the overall signal. In the most common MRI sequences, contrast 
between different types of tissue is generated by leveraging intrinsic relaxation 
properties of tissues, known as T1 and T2 relaxation, with the timing of excitation and 
readout radiofrequency (RF) pulses 11. These sequences produce images that are 
typically associated with MRI (Fig. 1.1). Alternate types of contrast can be generated 
by measuring properties of the 1H-containing molecules in the tissue such as 
concentration, macroscopic motion (due to vascular flow), microscopic motion 
(diffusion), and chemical exchange 12.  
Advanced Medical Imaging  
Advanced imaging techniques provide the opportunity to examine the cancer 
in alternate biologic domains that may determine therapeutic vulnerability in specific 
subsets. Such a strategy would complement the prevailing anatomic-based classifiers 
and could potentially address several clinical challenges when it comes to improving 
patient survival and optimizing drug discovery. These include the early detection and 
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discrimination of malignant disease, rapid assessment of treatment efficacy (including 
distinguishing pseudo-progression from true progression), and prediction of tumor 
recurrence. This type of information is difficult to gain from coarse anatomic imaging, 
although the field of machine learning and computer vision has recently sparked 
interest in this through radiomics studies 13,14. Instead, novel technologies have been 
developed in attempts to image the functional properties of cancer that are discovered 
through cancer biology research. This is achieved by measuring the uptake and/or 
utilization of molecular/metabolic contrast agents using primarily optical imaging, 
positron emission tomography (PET), and magnetic resonance (MR) techniques 15,16.  
Optical imaging has fantastic sensitivity and specificity for targeting cancer 
cells, which is why it is used in gold-standard diagnostic tools from ex vivo  
specimens 17. The main disadvantage of in vivo optical imaging is that the depth-of-
penetration of the photons is limited to at most a few cm 18. Thus, it is typically confined 
to intraoperative imaging during surgery, where it has proven successful at “painting” 
malignant tissue to aid in resection 19,20. PET is arguably the most common molecular 
imaging modality, and it is routinely used in the clinic to measure the uptake of 18F- 
fluorodeoxyglucose (FDG) in glycolytic tumors 21,22. However, in some cancers, the 
background signal is too high to produce sufficient contrast. This is most notable in 
prostate cancer, where the background signal originates from the excrement in the 
bladder, and brain cancer, where there is high uptake in surrounding healthy gray 
matter 23. There exist alternate PET agents which have shown promise in measuring 
brain tumor activity such as O-(2-18F-Fluoroethyl)-l-tyrosine (FET) 24,25, 6-18F-fluoro-L-
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3,4-dihydroxyphenylalanine (FDOPA) 26,27, and 11C-choline 28,29, although details of 
these agents are outside the scope of this project. 
 
Figure 1.1: Various types of contrast generated in MRI. Pulse sequences which exploit 
differences in T1 and T2 relaxation are visualized in the top row: T1-weighted post-
gadolinium contrast (A), T2-weighted (B), fluid-attenuated inversion recovery (C). 
Pulse sequences which quantify functional properties of the tumor and 
microenvironment are shown in the bottom row: perfusion imaging quantifying relative 
blood volume (rBV) (D), diffusion-weighted imaging quantifying apparent diffusion 
coefficient (ADC) (E), and chemical shift imaging (CSI) quantifying relative metabolite 
concentrations (F).  
Reproduced with permission from Keunen O, Taxt T, Grüner R, Lund-Johansen M, 
Tonn J-C, Pavlin T, Bjerkvig R, Niclou SP, Thorsen F. Multimodal imaging of gliomas 
in the context of evolving cellular and molecular therapies. Advanced Drug Delivery 
Reviews. 2014;76(1):98-115. (License number: 1049029-1). 
Multiparametric MRI of the Brain 
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Lastly, MR-based techniques such as nuclear magnetic resonance (NMR) and 
magnetic resonance spectroscopy (MRS) have demonstrated the capability of 
measuring both steady-state metabolite pool sizes as well as the metabolic flux of 
injected agents. Cancer metabolism and the MR-based techniques to measure it are 
discussed in detail in the following sections. 
 
Cancer Metabolism 
The metabolites found in a cell are the products of gene expression and protein 
activity and thus can reflect the overall state of a cell 30. Their concentrations also 
serve as feedback loops for certain cell regulation processes. For example, if a cell is 
too far away from a blood vessel and oxygen supply is low, oxidative phosphorylation 
becomes prohibitive. As a result, the HIF-1α transcription factor is activated which 
alters the cells homeostatic state to operate in hypoxic conditions. This could lead to 
the secretion of growth factors such as VEGF to stimulate angiogenesis for increased 
oxygen supply 31. Some mutations can even induce direct metabolic switches. The 
most well-known example is the IDH1/2 mutation found in many low-grade gliomas 32. 
Normally, IDH1/2 catalyzes the decarboxylation of citrate to alpha-ketoglutarate, but 
the mutated form shuttles alpha-ketoglutarate away from the TCA cycle and into 2-
hydroxyglutarate (2-HG) production. Thus, the accumulation of the oncometabolote 2-
HG is a direct indicator of the IDH1/2 mutation, and many MRI studies are attempting 
to detect it in vivo 33. When cancer cells rapidly proliferate, their metabolism begins to 
shift 34,35. Elevated glucose uptake increases the cells energy production which is 
necessary to grow and divide. The Warburg effect describes the phenomenon where 
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cancer cells allocate a substantial proportion of their pyruvate from the TCA cycle and 
oxidative phosphorylation to lactate fermentation 36,37 (Fig 1.2). This process is quicker 
at producing ATP, albeit not as efficient as oxidative phosphorylation. Moreover, it is 
postulated that this allows increased production of cellular building blocks such as 
choline and amino acids to provide the scaffolding for new cells. This shift to lactate 
production is the basis for in vivo hyperpolarized MR studies in this project. 
 
 
Figure 1.2: Visualization of the Warburg effect. Typical pyruvate utilization in 
differentiated cells is illustrated in (A). Oxidative phosphorylation is the preferred and 
most efficient method of generating ATP. Only when oxygen is scarce will lactate 
fermentation occur, which generates substantially fewer ATP molecules. In highly 
proliferative cells such as cancer, the majority of pyruvate is allocated to lactate 
fermentation, regardless of oxygen presence (B). 
Reproduced with permission from: Vander Heiden MG, Cantley LC, Thompson CB. 
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. 






Established MR-Based Techniques to Study Cancer Metabolism 
This section from my first-authored review is reproduced with permission from:   
Salzillo TC, Hu J, Nguyen L, Whiting N, Lee J, Weygand J, Dutta P, Pudakalakatti S, 
Millward NZ, Gammon ST, Lang FF, Heimberger AB, Bhattacharya PK. Interrogating 
Metabolism in Brain Cancer. Magnetic Resonance Imaging Clinics of North America. 
2016;24(4):687-703. (License number: 1049029-3) 
Detected Metabolites Using 1H MRS/NMR  
1H MRS/NMR is extensively used to monitor the steady-state levels of major 
endogenous cellular metabolites. For a full review of in vivo 1H MRS-detectable 
metabolites, see the following reference 38. In the field of neuro-oncology, the most 
prevalent metabolites in the 1H MR spectrum are N-acetylaspartate (NAA), total-
choline-containing metabolites (Cho), lactate (Lac), mobile lipids (Lip), creatine (Cre), 
glutamate (Glu), glutamine (Gln), glutamine + glutamate (Glx), glycine (Gly), 
glutathione (GSH) and 2-hydroxyglutarate (2-HG). NAA shows the largest signal in 
normal healthy brain tissue and typically decreases in gliomas 39. The Cho signal is a 
composite of free choline, phosphocholine (PC) and glycerophosphocholine (GPC), 
which are the precursors and breakdown products of the main membrane 
phospholipid phosphatidylcholine. The intensity of this peak is associated with cell 
proliferation and cell signaling and is typically elevated in cancer 40. As previously 
mentioned, lactate is the end product of aerobic glycolysis and is enhanced in cancer 
as described by the Warburg effect. Lipids (long chain fatty acids), especially lipid 
droplets known as mobile lipids or triglycerides, are rarely observed in the normal brain 
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but are often increased in glial tumors and are associated with cell death and 
increased necrosis 41. The Cre signal is a composite of creatine and phosphocreatine 
(PCr), which are involved in energy metabolism via the creatine kinase reaction. 
Creatine levels vary within normal brain regions and in some cases with  
tumorigenesis 42. The amino acid Glu is the most abundant amino acid in the brain 
and an essential neurotransmitter. In gliomas, glutaminolysis is often required for 
tumor growth as an anaplerotic source of carbon complementary to glucose 
metabolism 43. Recently, the oncometabolite 2-hydroxyglutarate (2-HG), which is 
produced in cells containing the isocitrate dehydrogenase (IDH) mutation, has been 
measured in patients with oligodendroglioma and astrocytoma tumors 44.  
Clinical 1H MRS/NMR Spectroscopy 
Numerous studies have highlighted the potential benefits of using 1H MRS to 
estimate metabolite levels in brain tumors in the clinic 45. When combined with similar 
spatial localization techniques that are used in generating anatomic MR images, this 
strategy can be used to produce maps of the variations in levels of Cho, Cre, NAA, 
Lac and Lip. With increased magnetic field strengths, improvements in scanner 
hardware and developments in software capabilities, the acquisition time for 
volumetric data is on the order of 5–10 minutes, and the spatial resolution of the voxels 
is typically 0.5–1 cm3 46. More recent advances in pulse sequence development and 
spectral editing schemes have facilitated the detection of metabolites with shorter T2 
relaxation times and lower signal-to-noise (SNR) ratios such a Glu, Gln, Glx, and 2-
HG, expanding the investigation of potential metabolic processes for both 
characterizing the spatial extent of gliomas and assessing therapeutic response. 
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For Tumor Characterization 
The first studies to identify metabolic differences between gliomas and normal 
brain tissue date back to the mid-1990s and used a long TE (144 ms) 1H MRS 
acquisition 47,48. Since then, numerous studies have shown that elevated levels of Cho 
and reduced levels of NAA together can distinguish regions of tumor from normal  
brain 49,50, define the spatial extent of abnormal metabolism due to tumor beyond the 
contrast-enhancing lesion 51,52, guide the selection of biopsied tissue samples to the 
most aggressive part of the tumor 53,54, and differentiate among tumor grades and 
types. The Cho-to-NAA index (CNI) is a metric that has been developed in the clinical 
setting to describe such changes and was found to be more robust than ratios and 
absolute quantification 55. These in vivo results have been confirmed by correlating 
with both ex vivo histological characteristics from image-guided tissue samples and, 
more recently, 1H high-resolution magic angle spinning of tumor biopsies to show that 
regions with elevated Cho and reduced NAA relative to normal brain have a high 
probability of corresponding to tumor 54. However, despite the benefits of 1H MRS in 
improving sensitivity to metabolically active tumor and differentiating gliomas from 
metastatic disease 56, other disease processes such as inflammation can also cause 
a reduction in neuronal function while increasing cellularity, so alone 1H MRS is not 
specific enough to differentiate tumor from inflammation 57.  
For Predicting Outcome or Response to Therapy 
In high-grade gliomas, higher Cho-to-Cre, higher Cho-to-NAA, higher Lac-plus-
Lip, and lower Cr-to-NAA abnormalities have been found to be associated with poor 
survival 58. In low-grade gliomas, far less data are available on the prognostic value of 
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MRS in the clinic. In one study, normalized Cre was found to be a significant predictor 
for tumor progression and for malignant tumor transformation in grade II gliomas. Low-
grade gliomas with decreased Cre appeared to have longer progression-free times 
and later malignant transformation than those with regular or increased Cre  
values 59. The information provided by MRS data is complementary to anatomic 
images and may often be more valuable than the contrast-enhancing lesion in 
assessing therapeutic response. The spatial extent of the metabolic lesion can also 
be used to plan focal therapy, such as external beam radiotherapy and gamma knife 
radiosurgery 60 as well as to assess the response to therapy 50. For example, it was 
demonstrated that mean tumor Cho/NAA ratio and normalized Cho decreased from 
baseline after completion of external beam radiotherapy  61. In this study, patients who 
exhibited more than a 40% decrease in normalized Cho between mid- and post-
radiotherapy studies were associated with shorter survival times and faster disease 
progression. The Lac/NAA ratio at the fourth week of radiotherapy and the change in 
normalized Cho/Cre between baseline and fourth week of radiotherapy were also 
predictive of outcomes, suggesting the possible benefit of adaptive, response-based 
radiation treatment. 
 
Hyperpolarized Magnetic Resonance  
Spin Polarization in MR 
The major limitation of NMR/MRS is that it is inherently an insensitive technique 
relative to the 1H concentration that is being measured. According to the nuclear 
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Zeeman effect, when an ensemble of nuclei is placed in a magnetic field, it will be split 
into two energy states according to their quantum spin when measured 62. These 
states are “spin up” (where the spins align parallel with the magnetic field) and “spin 
down” (where the spins align antiparallel with the field) 63. The number of nuclei in 
each state are denoted 𝑁𝑁− and 𝑁𝑁+, respectively, and as the “spin up” state is at lower 
energy, it contains slightly more nuclei than the “spin down” state. From the quantum 
mechanics framework, this is an overgeneralization as the spins technically exist in a 
linear combination of the two states, but for the sake of illustrating the concept for this 
project, this model should suffice. The population of the two states is governed by the 







𝑘𝑘𝐵𝐵𝑘𝑘                                                                                                               Equation 1 
Where Δ𝐸𝐸 is the energy difference between the states, 𝛾𝛾 is the gyromagnetic ratio of 
the nuclei, ℏ is the reduced Planck’s constant, 𝑘𝑘𝐵𝐵 is the Boltzmann constant, and 𝑇𝑇 is 
the temperature. Because the exponent is small at clinical magnet strengths and room 







                                                                                                                       Equation 2 
Rearranging this equation yields: 









(𝑁𝑁− + 𝑁𝑁+)�                                                     Equation 3 









                                                                                                           Equation 4 
At clinical magnet strengths and room temperature, the ensemble polarization, which 
is proportional to the MR signal, is only a few parts per million (ppm). Therefore, the 
primary requirement to achieve an acceptable SNR for medical imaging is that a large 
concentration of nuclei must be measured. Fortunately, the concentration of water in 
the brain gray matter is approximately 40 M 64, so the low polarization is compensated 
for, allowing for the production of exquisite anatomic images.  
Molecular and Metabolic MR 
In order to detect a sufficient SNR from lower concentration molecules such as 
metabolites (which exist on the order of 10 mM in tissue), a large number of averages 
must be acquired, resulting in lengthy scan times. Thus, metabolites are often 
measured in “steady-state” where the pool size of the metabolite is reported as 
previously discussed in 1H MRS studies. Alternatively, isotopically-enriched metabolic 
substrates (often 13C-labeled) can be infused into the subject, and the gradual 
incorporation of the label into its metabolic products can be measured over the course 
of several hours in a process known as stable isotope tracing 65–67. If the number of 
requisite averages to detect the label could be reduced by implementing a method to 
increase the polarization (and hence MR-signal of the substrate and products), the 
necessary scan time of these experiments could be vastly decreased, and accurate 
metabolic conversion rates could be measured in real-time. This is exactly what is 
achieved with a novel technique known as hyperpolarized magnetic resonance, which 




There are four established hyperpolarization methods: brute force 68,69, 
parahydrogen-induced 70,71, optically-pumped 72,73, and dynamic nuclear polarization 
(DNP) 74,75 (Fig. 1.3). DNP was exclusively used in this project. In this process, an 
isotopically-enriched metabolic substrate is doped with free electron radicals and 
cooled down to solid state at temperatures of a few kelvin. At these temperatures, the 
polarization of the electrons nearly reaches unity. The sample is then repeatedly 
irradiated with frequency-selective microwaves which transfers the polarization from 
the free electrons to the isotopically-enriched nuclei via the nuclear Overhauser  
effect 76,77. The ensemble of nuclei is split into two distributions- a thermally polarized 
pool and a hyperpolarized pool- and the overall polarization of the ensemble 
represents a superposition of these states. Overall polarization levels of over 10,000-
fold can be achieved with this process. However, what drove this technique to be 
clinically translatable was the engineering of a method to rapidly reheat and dissolve 
the hyperpolarized substrate into an injectable solution 78. This process is known as 
dissolution DNP (dDNP), and Oxford Instruments engineered a preclinical system to 
reliably perform this procedure for academic research, which was used in this project. 
General Electric has recently manufactured a clinical-grade system called the 
SPINLab which adds processes to filter out toxic materials such as the free-radicals 





Figure 1.3: Instrumentation of two of the common hyperpolarization techniques. 
Dynamic nuclear polarization is illustrated in (A), which is the most commonly used 
hyperpolarization technique and has been used in clinical trials. Parahydrogen-
induced polarization is illustrated in (B), which has found recent success in achieving 
high levels of polarization for a wide range of nuclei.  
Reproduced from: Dutta P, Salzillo TC, Pudakalakatti S, Gammon ST, Kaipparettu 
BA, McAllister F, Wagner S, Frigo DE, Logothetis CJ, Zacharias NM, Bhattacharya 
PK. Assessing Therapeutic Efficacy in Real-time by Hyperpolarized Magnetic 
Resonance Metabolic Imaging. Cells. 2019;8(4):340. (Open access) 
 
Hyperpolarization in MR 
Because the hyperpolarized pool of nuclei is in a non-equilibrium state, the 
polarization will quickly begin to degrade once the sample is heated and removed from 
microwave irradiation, and eventually the ensemble of nuclei will be composed of only 
the thermally polarized pool whose polarization is described by Equation 4. The rate 
of this depolarization is equivalent to the T1 relaxation of the ensemble, and thus 
different nuclei have unique hyperpolarized lifetimes 79. Additionally, once the 
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hyperpolarized solution is injected into a subject laying in the magnet, the process of 
exciting the nuclei with RF irradiation during imaging or spectroscopy and extracting 
the amplified signal results in the transfer of nuclei from the hyperpolarized pool to the 
thermally polarized pool (Fig. 1.4). This causes a fraction of the overall polarization of 
the ensemble of nuclei to be non-renewably depleted until the ensemble is composed 
entirely of the thermally polarized pool. The amount of depolarization is proportional 
to the RF power (and thus flip angle) used to excite the spins. Therefore, pulse 
sequences need to be carefully designed to quickly acquire data and avoid using large 
flip angles in order to optimally utilize the hyperpolarization of the sample.  
Common pulse sequences used in hyperpolarized MR are either repeated 
single-voxel magnetic resonance spectroscopy (MRS) or multi-voxel magnetic 
resonance spectroscopic imaging (MRSI) 80–82. Single-voxel MRS is faster at acquiring 
each repeated excitation but contains no spatial distribution information. Multi-voxel 
MRSI has the advantage of producing parametric maps (usually of the metabolite 
signals or their exchange rates) but acquires repeated excitations at a slower rate and 
can suffer from distortions due to B0 and B1 inhomogeneity. Because there is typically 
sufficient SNR in one excitation to detect the hyperpolarized substrate and its 
metabolic products, spectra from repeated excitations can stacked, rather than 
averaged. This allows the evolution of the hyperpolarized label to be measured in a 
cine-like manner with time resolutions of 2-10 s. The signal evolution of the injected 
substrate and its metabolites can be analyzed ratiometrically 83 or through kinetic 




Figure 1.4: Polarization states during conventional and hyperpolarized MR 
experiments. During conventional MR experiments, the ensemble of nuclei is 
comprised of a thermally polarized pool which follows a Boltzmann distribution (A). 
The polarization levels remain constant before and after a pulse sequence which 
contains an RF excitation pulse with flip angle, α, and repetition time, TR. During 
hyperpolarized MR experiments, the ensemble of nuclei is comprised of a 
hyperpolarized pool with some subset of nuclei left in the thermally polarized pool (not 
depicted) (B). The overall polarization level is initially high, but it decreases throughout 
a pulse sequence due to both RF excitation and time between the excitations as nuclei 
equilibrate to the thermally polarized pool.  
 
 
Existing Hyperpolarized MR Literature  
There have been several reviews published on various metabolic substrates 
used in hyperpolarized MR 86,87 and their clinical applications of diagnosing a number 
of tumor types 88 and measuring their response to therapy 89,90. Pyruvate is the most 
commonly used hyperpolarized substrate due to its relatively long hyperpolarization 
lifetime and central role in tumor metabolism via the Warburg effect. There have been 
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several published preclinical studies using hyperpolarized [1-13C]pyruvate in vivo to 
distinguish brain tumors from healthy brain 91–95 as well as to measure the response 
of brain tumors to therapies such as radiotherapy 96, temozolomide 97, VEGF  
inhibitors 98, and glycolytic inhibitors 99. The success of these studies helped justify 
the initiation of several clinical trials for the use of hyperpolarized pyruvate in brain 
cancer, which have produced human data from healthy volunteers 100–102 and glioma 
patients 103–106. Given the current advances, there is a strong likelihood that 
hyperpolarized pyruvate MR will be adopted in the clinic with FDA approval for 
metabolic imaging of brain cancer, and protocols for integrating this technique into the 
clinical workflow are underway 107. 
 
Dissertation Overview 
The work presented in this dissertation was initiated with the goal of utilizing 
current and emerging MR technologies to study the metabolism of brain cancer and 
address several clinical challenges associated with the diagnosis and treatment of this 
disease. Specifics of the technologies and experimental methodologies used in this 
research are outlined in CHAPTER 2. Preliminary anatomic and metabolic data on a 
panel of patient-derived GBM xenograft mouse models are presented in CHAPTER 
3. One of these mouse models was chosen for the bulk of this project, detailed in 
CHAPTER 4, which describes the anatomic and metabolic evolution of GBM as it 
progresses through tumor development, regression following radiotherapy, and 
eventual recurrence to the point of relapse. Lastly, supplemental data describing the 
metabolic profile of cancer-associated immune cells are presented in CHAPTER 5. 
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These data were produced in collaboration with several laboratories at MD Anderson 
and form the basis of a potential future project of measuring the metabolic response 





CHAPTER 2:  
GENERAL METHODS 
Cell Lines 
Glioma sphere-forming cells (GSC): GSCs were isolated from surgical samples 
from patients which have been reported in the literature 108. The specific GSC lines 
that were selected for this project were 8-11, 262, 272, 231, 248, and 275. As reported 
in the literature 109,110, cells were grown in Neurosphere Media containing DMEM/F12 
(Corning) with B27 (x1, Thermo Fisher Scientific), bFGF (20 ng/ml, MilliporeSigma), 
and EGF (20 ng/ml, MilliporeSigma) at a temperature of 37° C. These cells were 




Mice: Five-week-old athymic nude mice (Experimental Radiation Oncology, MDACC) 
were used for in vivo studies. Mice were housed together in a sterilized facility with 5 
to a cage, so only females were used as they are less-prone to fighting with each 
other. Mice received standard feed and water and were inspected for health daily. A 
guide-screw system was used for implantation to allow for consistent placement of 
intracranial xenografts as described in literature 111. A 2.6 mm long guide screw with 
a 0.5 mm channel bored through its center was drilled into the skull directly over the 
caudate nucleus. After the mice had recovered for 2 weeks, 5 × 105 GSC 8-11 cells 
were suspended in 3 µL of phosphate-buffered saline (PBS) and injected 
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stereotactically through the bore of the guide screw over a period of five minutes. After 
injection, a stylet was placed in the bore of the screw to close the system and prevent 
tissue from growing inside. Control animals were prepared in the same manner except 
that PBS absent of GSCs was injected. All procedures were performed in accordance 
with regulations of the Institutional Animal Care and Use Committee (IACUC) of the 
University of Texas MD Anderson Cancer Center. 
Anatomic Magnetic Resonance Imaging 
Tumor anatomy was visualized with MRI on a Bruker 7 T pre-clinical scanner (Bruker 
Biospin MRI GmbH) every 3 days. T1-weighted (T1-w), T2-weighted (T2-w), and fluid 
attenuated inversion recovery (FLAIR) 1H pulse sequences were implemented. A 35 
mm RF volume coil (Bruker) was used to acquire the images. The following pulse 
sequences and parameters were used:  
• Coronal, sagittal, and axial T2-w (FA = 90°, TE = 6.5 ms, TR = 1500 ms, BW = 
75 kHz, Matrix = 256 x 192, FOV = 25 mm x 25 mm (axial 20 mm x 20 mm), 
NEX = 4, Slice Thickness = 0.75 mm, Slice Gap = 0.25 mm, RARE Factor = 12) 
• Axial T2-w FLAIR (FA = 90°, TE = 48 ms, TR = 10,000 ms, TI = 2000 ms, BW 
= 38 kHz, Matrix = 256 x 192, FOV = 20 mm x 20 mm, NEX = 3, Slice Thickness 
= 0.75 mm, Slice Gap = 0.25 mm, RARE Factor = 10, Fat Suppression on) 
• Axial T1-w (FA = 90°, TE = 57 ms, TR = 3000 ms, BW = 85 kHz, Matrix = 256 x 
192, FOV = 20 mm x 20 mm, NEX = 3, Slice Thickness = 0.75 mm, Slice Gap 




Tumor Volume Measurements 
DICOM images from the T1-w, T2-w, and FLAIR pulse sequences were imported into 
3D Slicer software 112. Tumors were segmented on each slice of the coronal, sagittal, 
and axial T2-w images. T1-w and FLAIR images were used to confirm tumor 
boundaries and differentiate tumor tissue from surrounding edema and cerebral spinal 
fluid. Volume in each plane of the T2-w images was calculated by multiplying the 
number of voxels within the tumor segmentation by the spatial dimensions of the 
voxels. The calculated volumes from each of the three T2-w imaging planes were 
averaged together to give the final volume measurement of the tumor. At least 5 tumor 
volumes were averaged at each time-point.  
Hyperpolarized Sample Preparation 
[1-13C]pyruvic acid (MilliporeSigma) was doped with Ox063 trityl radical (Oxford 
Instruments) to 15 mM concentration. 20 µL of this solution was mixed with 0.4 µL of 
50 mM Gd3+ (Bracco Diagnostics). This solution was placed in a DNP HyperSense 
(Oxford Instruments) to polarize for approximately 1 hour under microwave irradiation 
at 94,100 GHz. An average polarization of 20,000 was achieved. Once the sample 
was prepared, it was rapidly heated and dissolved in 4 mL buffer comprised of 40 mM 
2-Amino-2-(hydroxymethyl)-1,3-propanediol (TRIS; MilliporeSigma), 80 mM NaOH, 
0.1 g/L ethylenediaminetetraacetic acid (EDTA; MilliporeSigma), and 50 mM NaCl. 
This solution had a final [1-13C]pyruvic acid concentration of 80 mM which was then 




13C Magnetic Resonance Spectroscopy 
A 72 mm 1H volume coil (Bruker Biospin MRI GmbH) was used to acquire anatomic 
images for accurate region of interest (ROI) placement for spectroscopy. A 13C 
transmit/receive surface coil (Doty Scientific Inc) was placed above the skull, directly 
over the tumor. A 13C slice-selective, pulse-acquired spectroscopy sequence was 
prepared in which a single slice was placed over the tumor (FA = 25°, TE = 205 ms, 
TR = 2,000 ms, BW = 5 kHz, Matrix = 2048 x 64, FOV = 35 mm x 35 mm, NEX = 1, 
Slice Thickness = 6 mm, reference frequency = 75.515 MHz). Spectra were acquired 
every 2 seconds for 2 minutes to detect [1-13C]pyruvate and its lactate product.  
Pyruvate-To-Lactate Measurements 
The time-resolved stack of 13C MR spectra was imported into MATLAB (The 
MathWorks, Inc.). A freely-available MATLAB script courtesy of the Hyperpolarized 
MRI Technology Resource Center (Hyperpolarized-MRI-Toolbox. Available online at: 
https://github.com/LarsonLab/hyperpolarized-mri-toolbox  
DOI: 10.5281/zenodo.1198915) was used to analyze the spectra. This script was 
adapted so that each of the individual spectra in the time-resolved stack could be 
phase- and baseline-corrected individually, rather than as a sum. Following these 
corrections, the pyruvate and lactate peaks were integrated (full-width, quarter-max), 
and the integral values were summed across all spectra in the time-resolved stack. 
The metric for pyruvate-to-lactate conversion, denoted as nLac, was then calculated 
using these values as the ratio of lactate/(lactate+pyruvate). At least 5 nLac 
measurements from tumor-bearing mice were averaged at each time-point. 
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Additionally, N = 3 nLac measurements from control mice were averaged and 
compared with tumor-bearing mice at these time-points.   
Brain Sample Excision  
Mice were euthanized and the bolt and top of the skull were carefully removed to 
expose the brain. The optical tracts were severed, and the intact brain was excised. 
For samples to be processed for immunohistochemistry (IHC) analysis, the entire 
brain was placed and fixed in a vial containing 10% formalin. 
For samples to be processed for NMR spectroscopy, incisions were made along the 
longitudinal and transverse fissures. The tissue within the left cerebral hemisphere 
(which contained the GSC injection site) was isolated from the remainder of the brain 
(which included the olfactory bulb, right cerebral hemisphere, and cerebellum). The 
isolated tissue was flash-frozen in liquid nitrogen and transferred to a freezer at -80°C. 
This process was executed as quickly as possible to preserve cellular metabolism, 
and the same volume of tissue was collected across all time-points, regardless of 
tumor size.  
Sample Preparation for Metabolite Extraction 
Metabolites were extracted from ex vivo samples as described in the literature 113. 
Frozen samples were pulverized and weighed. The tissue particles were transferred 
to a conical centrifuge tube containing 2 mL of methanol, 1 mL of water, and 0.5 mL 
of lysing beads. The samples were vortexed, flash-frozen, and thawed for 3 cycles to 
lyse the cells. The samples were then centrifuged at 4° C for 10 minutes, and the 
supernatant, which containined water, methanol, and dissolved metabolites, was 
24 
  
extracted. The methanol was evaporated under reduced pressure using a rotary 
evaporator, and the remaining solvent was freeze-dried using a lyophilizer. The dried 
product was dissolved in 600 µL of deuterium oxide, 36 µL of phosphate buffered 
saline, and 4 µL of 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS-d6) as the NMR 
reference standard (500 µM in solution). The final 640 µL solution was transferred to 
a 5 mm NMR tube. All supplies (deuterium oxide, DSS, phosphate buffer) were 
purchased from MilliporeSigma and used without further purification.   
Nuclear Magnetic Resonance Spectroscopy 
NMR spectra were obtained using a Bruker AVANCE III HD® NMR scanner (Bruker 
Biospin MRI GmbH) at a temperature of 298 K. The spectrometer operates at a 1H 
resonance frequency of 500 MHz and is endowed with a triple resonance (1H, 13C, 
15N) Prodigy BBO cryogenic temperature probe with a Z-axis shielded gradient for 
increased sensitivity. A pre-saturation technique was implemented for water 
suppression. The spectra were obtained with a 90º pulse width, a scan delay trel of 6 
s, a 10240 Hz spectral width, and an acquisition time tmax of 1.09 s (16,000 complex 
points). A total of 256 scans are collected and averaged for each spectrum, which 
resulted in a total scan time of 33 minutes. Here, trel + tmax is nearly 8 s so that it 
exceeds 3*T1 for the metabolites observed. The time domain signal is apodized using 
an exponential function. 
Metabolite Pool Size Measurements 
The raw FID files from the spectrometer were imported into MestreNova software 
(Mestrelab Research) where they were Fourier transformed into chemical shift 
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spectra. The spectra were manually phase-corrected to form Lorentzian peak shapes 
and manually baseline-corrected to remove the noise floor, and the DSS reference 
peak was set to 0 ppm. The processed spectra were exported to Chenomx NMR Suite 
8.1 software (Chenomx Inc.) where the peaks were identified by matching them to 
spectral models of metabolites contained in the database. The identified peaks were 
integrated in MestreNova, and the peak areas were normalized to the peak area of 
DSS. As described in the literature 114, these values were further normalized to the 
mass of the pulverized tissue (in mg) and converted to metabolite concentrations (in 
µM) by implementing the Beer-Lambert law. The final values were reported as µM/mg. 
Similar to the nLac measurements, there were N = 5 groups of measurements for 
tumors and N = 3 groups of measurements for healthy brain controls at each time-
point.  
Sample Preparation for Immunohistochemistry 
Mice were sacrificed by intracardiac perfusion of PBS and 4% paraformaldehyde. 
Brains were removed, fixed in 10% formalin for at least 24 hours and embedded in 
paraffin. Sections (5 µm) were cut for immunohistochemical analysis. 
Immunohistochemistry 
Sections of formalin-fixed paraffin-embedded mouse brain specimens were 
deparaffinized with xylene and rehydrated through a graded alcohol series, followed 
by distilled water and PBS. The slides were processed for antigen retrieval by 
pressure cooker in citrate buffer (pH 6.0) for 20 minutes. The slides were incubated 
overnight with the mouse antihuman monocarboxylate transporter 1 (MCT1) antibody 
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(Santa Cruz Biotechnology) at 1:200 dilution and rabbit antihuman lactate 
dehydrogenase-A (LDH-A) antibody (Abcam) at 1:100 dilution.  For the MCT1 
immunostaining, slides were incubated with Mouse Ig Blocking Reagent (Vector 
Laboratories) to reduce endogenous mouse Ig staining. The slides were rinsed with 
PBS and incubated with Anti-rabbit Poly-HRP-IgG (Leica Biosystems) and Polymer 
Anti-Mouse IgG reagent (Leica Biosystems) and visualized with 3,3′-
Diaminobenzidine (DAB). The slides were counterstained with hematoxylin, 
dehydrated and coverslipped.  
Protein Expression Measurements 
The 40x images (1360 x 1024 pixels) of MCT1 and LDH-A stains were loaded into the 
FIJI package of ImageJ 115. Color deconvolution was performed 116 to extract the DAB 
stain from the image. These DAB images were thresholded so that DAB signal was 
set to 1 and everything else was set to 0. Three nonoverlapping, uniformly-sized ROI 
(340 x 256 pixels) were randomly placed in the tumor and one ROI outside the tumor 
as a background measurement. The percent area of DAB stain was calculated in 
these ROI (number of DAB-positive pixels divided by number of pixels in ROI). Percent 
area from the background ROI was subtracted from each of the tumor ROI which were 
then averaged together to produce the final metric for protein expression in that image. 
Average percent area from each image at a time-point were further averaged together 






All statistical analysis was conducted using GraphPad Prism 8 (GraphPad Software). 
All measurements are reported as the mean value ± standard deviation, and error 
bars in the figures represent standard deviation. N represents the sample size for each 
group as a single number or range of values. Statistics are described in detail for each 







PRELIMINARY ANTOMIC AND METABOLIC IMAGING OF A PANEL OF 
PATIENT-DERIVED GBM XENOGRAFTS 
Motivation 
Cancer is a heterogenous disease with varying phenotypes, even within the 
same type of cancer. In fact, within a tumor, there are heterogenous subregions of 
cells which possess varying mutational, proteomic, and metabolic profiles 117,118. As a 
tumor grows and reacts to its microenvironment or other stimuli, dominant profiles 
emerge which can alter overall tumor behavior over time. This heterogeneity is what 
makes cancer so difficult to treat. Two patients can experience vastly different tumor 
evolutions and symptom development. Furthermore, these patients can respond to 
the same treatment completely differently. Even if the treatment is initially successful 
and drives the tumor into remission, the remnants of the tumor can adapt and develop 
resistance as its dominant profiles change which leads to recurrence and eventual 
relapse.  
The Cancer Genome Atlas (TCGA) identified initially four subtypes of GBM 
which has since been narrowed down to three (classical, mesenchymal, and 
proneural) based on genetic and transcriptome analysis of over 600 GBM  
tumors 119,120. This data has been analyzed to predict clinical outcomes of these 
subtypes such as overall survival and response to therapy 121. We wanted to take this 
one step further and determine tumor aggressiveness non-invasively with 
hyperpolarized MR. This proposal was motivated by a prior study in our laboratory 
which demonstrated that significant differences of hyperpolarized pyruvate-to-lactate 
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conversion and metabolite pool sizes existed between groups of patient-derived 
pancreatic xenograft murine models with varying median survival times 122. 
In collaboration with the MD Anderson Brain Tumor Center and laboratory of 
Dr. Frederick Lang, we sought to produce orthotopic murine models of GBM from a 
panel of authenticated patient-derived glioma sphere-forming cell (GSC) lines. Six 
GSC lines were chosen which spanned the original four TCGA subtypes and were 
paired by median survival time of either one, three, or six months (unpublished data). 
These GSC lines were 8-11, 262, 272, 231, 248, and 275. Before ordering large 
cohorts of mice, preliminary imaging experiments were performed as a proof-of-
concept. In addition to validating the nominal median survival and measuring rough 
growth curves to plan the timing of metabolic assays, we needed to establish that it 
was possible detect sufficient hyperpolarized pyruvate and lactate signal from the 
brain tumors. Mouse vasculature, blood brain barrier permeability, tumor perfusion, 







Preliminary Anatomic MRI and Hyperpolarized 13C MRS Of GSC Tumor-Bearing Mice. 
Tumor aggressiveness of each GSC line was verified by measuring the time-
to-target-volume and survival of the tumor-bearing mice. Anatomic MRI was 
performed on the six groups of GSC tumor-bearing mice at various times throughout 
development. Tumor volume was calculated from these scans and plotted over time 
to form tumor growth curves (Fig. 3.1A). The maximum time to reach a target tumor 
volume of 25 mm3 for each GSC line is as follows: 28 days (8-11), 41 days (262), 40 
days (272), N/A days (231), 152 days (248), and 195 days (275). Because the volume 
measurements are fairly sparse at the early time-points (due to scanner availability), 
the actual time to reach this volume could occur before these reported time-points.  
Hyperpolarized MRS experiments were also performed in five of the six groups 
of GSC tumor-bearing mice (Fig. 3.1B). GSC 231 had abnormally low nLac values 
due to poor SNR. However, all but one of the remaining nLac measurements were 
greater than 0.3 with an average value of 0.40 ± 0.14.  
The mouse survival produced by each of the GSC lines is shown in Fig 3.1C. 
Some of the data is censored due to mouse euthanasia and tumor excision for ex vivo 
analysis. Median survival for each of the GSC lines is as follows: 34 days (8-11), 39 
days (262), 59 days (272), N/A days (231), 154 days (248), and 203 days (275).  
Many of the hyperpolarized MRS experiments were performed on different 
days, so the change in nLac over the course of tumor development was investigated 
by plotting nLac against time after implantation. However, the different GSC lines 
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produced varying survival times, so the same date after implantation corresponded to 
a unique point in tumor development for each GSC line. Thus, the day at which the 
hyperpolarized MRS experiments were performed was divided by the survival of the 
corresponding mouse in attempts to normalize the stage of tumor development 
between the GSC lines. Excluding the abnormally low nLac values in the GSC 231 
tumor-bearing mice, nLac was plotted against this normalized tumor development time 
(Fig 3.1D), and it can be seen that all of the hyperpolarized MRS experiments were 
conducted at > 70% survival. A positive linear trend in nLac over time with a slope of 





Figure 3.1: Preliminary anatomic MRI and hyperpolarized 13C MRS of GSC tumor-
bearing mice. Average tumor volume, measured from anatomic MRI, is plotted as a 
function of time for each of the GSC lines (A). Individual nLac values, measured with 
hyperpolarized 13C MRS, are plotted for the different GSC lines (B). The survival curve 
for each of the GSC lines are plotted in (C). The time-points of each of the 
hyperpolarized MRS experiments in (B) were normalized to the survival of the 
corresponding mouse to convert the time-points from days to % Survival. Individual 







While the number of data points for each GSC line was too sparse to conduct 
advanced statistical analysis, this preliminary project served its purpose as a proof-of-
concept that pyruvate-to-lactate conversion could reliably be detected in brain tumors 
using our hyperpolarized MRS protocol. Furthermore, a general idea of the tumor 
growth rate and median survival of the GSC lines was gained. Collectively, these data 
allowed us to rank the aggressiveness of the GSC lines (from most aggressive to 
least: 8-11, 262, 272, 231, 248, 275), so an a priori hypothesis of how the nLac data 
would vary among the different lines could be formed. Lastly, this preliminary project 
provided me with the experience with these experimental methods to have confidence 
to perform them independently and understand their challenges so that I could 
optimally design my experiments and troubleshoot any potential errors.  
Following this initial analysis of the six GSC models, the goal was to expand 
the sample size of each group of mice in order to establish statistical power for the 
original hypothesis: that measuring tumor metabolism with hyperpolarized MRS and 
NMR spectroscopy could predict GBM tumor aggressiveness. An a priori power 
analysis was conducted using a power of 0.8, Type I error probability of 0.05, and 
effect size which was estimated from the hyperpolarized MRS and NMR spectroscopy 
data acquired in the aforementioned pancreatic cancer project 122. Significant 
differences between any of the two groups for the hyperpolarized MRS experiments 
were expected with a sample size of 3, and between 2 and 6 for the various 
metabolites from the NMR spectroscopy experiments. Thus, it was planned to include 
N = 5 mice per group.  
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When performing these experiments on GSC models with varying survival 
times, an imperative factor to consider is at what point during tumor development to 
acquire these measurements to ensure that the results are comparable between GSC 
models. In other words, at what time does tumor metabolism stabilize so that it is 
possible to accurately compare the results between GSC models without having the 
stage of tumor development confound the results? Many studies pick an arbitrary time-
point during development to perform these experiments. Alternatively, other reports 
wait until the tumor is an arbitrary size to conduct the metabolic imaging experiments. 
However, a common size among different GSC lines does not ensure that they will 
also possess same metabolic maturity.   
The positive linear trend of nLac that was observed in Fig. 3.1D was particularly 
interesting because it suggested that conversion of hyperpolarized pyruvate to lactate 
was increasing throughout the latter half of tumor development. I wondered if this trend 
could be extrapolated back to early tumor development. This marked a major 
crossroads for my PhD project. If changes in tumor metabolism could not be detected 
with hyperpolarized MR and NMR spectroscopy throughout tumor development, then 
a metabolic equilibrium should exist such that I could choose a time-point to 
confidently compare the results between GSC lines, and I could attempt to predict 
tumor aggressiveness through these modalities as originally intended. However, if 
significant changes in tumor metabolism could be detected with hyperpolarized MR 
and NMR spectroscopy throughout tumor development, then alternative clinical 
applications of this technology could be explored such as early detection of GBM 
malignancy or improving diagnostic and prognostic capabilities. Furthermore, this 
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longitudinal approach of studying the metabolic evolution of these tumors could also 
be applied to investigate post-therapy events such as tumor regression and eventual 
recurrence.  
Therefore, the theme of this project transformed from measuring the metabolic 
differences between several GSC lines at one time-point to measuring the metabolic 
evolution of one GSC line at several time-points. GSC 8-11 was chosen from this 
panel of tumors because it was a highly aggressive cell line, and existing data 
(unpublished) demonstrated that the tumors responded relatively well to radiotherapy. 
Taking time as a common dimension, the individual development of tumor anatomy 
and metabolism as well as their interrelationship could be studied throughout all 
stages of tumor progression. This led to the formation of the central hypothesis of my 




Central Hypothesis, Specific Aims, and Rationale 
Central Hypothesis: Throughout each stage of glioblastoma progression 
(development, regression, and recurrence), significant metabolic changes of the 
tumor can be detected prior to significant anatomic changes. 
Specific Aim 1: Track the anatomic and metabolic evolution of GBM during 
tumor development. Following orthotopic GBM cell implantation, the mice will be 
imaged periodically with conventional anatomic MRI pulse sequences to measure 
tumor volume over time. Then at specific time-points throughout tumor development, 
hyperpolarized MRS experiments will be performed to measure the dynamic 
conversion of pyruvate to lactate in vivo. Following hyperpolarized MRS experiments, 
tumors will be excised and prepared for global metabolomic analysis with NMR and 
IHC.  
Specific Aim 2: Administer radiation therapy to GBM and measure the anatomic 
and metabolic response during tumor regression. At around 75% through tumor 
development, radiation therapy will be delivered to the brains of tumor-bearing mice. 
Tumor volume and pyruvate-to-lactate conversion will then be measured throughout 
tumor regression as described in SA 1. Tumors will again be excised following 
hyperpolarized MRS experiments for global metabolomic analysis. 
Specific Aim 3: Monitor the anatomic and metabolic states of regressed GBM 
tumors to the point of relapse. Following tumor regression from radiation therapy, 
mice will be imaged each week to measure tumor volume and pyruvate-to-lactate 
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conversion until the eventual recurrence of the tumor. Tumors will not be excised for 
this aim in order to produce longitudinal measurements of the same mouse. 
Rationale: If metabolic changes in these aggressive tumors could be detected more 
rapidly than anatomic changes, then physicians could augment their existing protocols 
with these techniques to achieve several clinical benefits. In addition to the 
aforementioned possibilities of early detection of malignancy and improved diagnostic 
and prognostic capabilities, current challenges include distinguishing 
pseudoprogression from true progression following therapy, rapidly quantifying 
treatment response, and predicting recurrence. During tumor development, early 
detection of malignant transformation would allow physicians to administer therapy 
sooner while the tumor is less invasive and in a more treatable state, leading to 
improved patient outcomes. Assessing true tumor response shortly after the 
administration of therapy would provide physicians with the information of whether a 
treatment was effective, giving them more time to shift their strategy if the tumor 
continued to progress. Lastly, detecting early tumor recurrence during follow-up 
exams before the patient fully relapses would allow physicians to take early corrective 
action before the recurrent tumor becomes unmanageable. In each stage of tumor 
progression, detecting alterations in metabolic activity prior to anatomic changes in 
these aggressive cancers would ultimately improve the chance of patient survival.   
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CHAPTER 4:  
MEASURING THE METABOLIC EVOLUTION OF GLIOBLASTOMA 
THROUGHOUT TUMOR DEVELOPMENT, REGRESSION, AND RECURRENCE 
WITH HYPERPOLARIZED MAGNETIC RESONANCE 
Introduction 
There is still much to be explored to determine how hyperpolarized MR can 
impart a positive clinical impact in the treatment of brain tumors. The aforementioned 
preclinical studies discussed in INTRODUCTION (Chapter 1) do a thorough job of 
elucidating differences in pyruvate utilization between tumors and healthy brain or 
between untreated and treated tumors, but they only do so at one point during 
development or with one pre- and post-treatment measurement. Tumor metabolism is 
heterogeneous and evolves over the course of tumor development suggesting that 
the time-point of the measurement can significantly impact the results 123–125. 
Following treatment, metabolism is similarly dynamic as it responds to therapeutic 
insults before gaining resistance or re-growing. This complex metabolic trajectory 
cannot be captured with one post-treatment measurement alone. Therefore, we 
sought to implement for the first time, a series of serial hyperpolarized MRS 
measurements at multiple time-points over the course of tumor growth and treatment 
regimen. In vivo hyperpolarized pyruvate-to-lactate conversion values were obtained 
at multiple time-points throughout three stages of tumor progression (development, 
regression following radiotherapy, and recurrence to the point of relapse). Additionally, 
the novel use of hyperpolarized MRS to assess brain tumor recurrence, which is an 
unfortunate and inevitable reality for most GBM patients, could improve patient 
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survival by informing physicians when additional treatment is necessary before the 
tumor aggressively regrows 126,127.  
The purpose of this study was to compare hyperpolarized pyruvate-to-lactate 
conversion values from the serial hyperpolarized MRS experiments with tumor volume 
changes that were acquired with anatomic MRI during each stage of tumor 
progression (Fig. 4.1). This analysis was performed to demonstrate the value of 
adding hyperpolarized MR to conventional imaging protocols by addressing several 
challenges commonly encountered in the clinical setting. Furthermore, we sought to 
form a more complete picture of the metabolic events occurring throughout tumor 
progression by performing global metabolomics with NMR spectroscopy and protein 
expression assays with IHC on ex vivo tumor samples at multiple time-points. Lastly, 
correlative analysis was performed to investigate the interrelationship of each of these 





Figure 4.1: Anatomic and metabolic imaging of tumor-bearing mice over time. Tumor 
volume (A), imaged with T2-weighted MRI, and pyruvate-to-lactate conversion (B), 
measured with hyperpolarized MRS, is displayed at the end of tumor development 
(Day 34), end of tumor regression (Day 55), and at the point of relapse (Day 68) in the 









Refer to GENERAL METHODS in Chapter 2 for detailed discussion of experimental 
methods. Specific methods for this project are given below.  
Experimental Overview 
Following the intracranial implantation of patient-derived GSCs, the anatomic and 
metabolic properties of this GBM model were interrogated at several time-points 
during three stages of tumor progression: tumor development, regression following 
radiotherapy, and eventual recurrence. Mice were split into three cohorts: untreated 
tumor-bearing mice, treated tumor-bearing mice (2x5 Gy radiotherapy), and control 
mice. Anatomic growth and shrinkage were studied in vivo with T1-weighted, T2-
weighted, and fluid-attenuated 1H MRI. Real-time conversion of injected pyruvate to 
lactate was measured in the tumor in vivo with hyperpolarized 13C MRS. Ex vivo 
metabolite pool sizes and protein expression were determined with NMR 
spectroscopy and IHC, respectively. All measurements were acquired within ±1 day 
of their nominal time-point.  
Tumor Radiotherapy 
Tumor-bearing mice in the treatment cohort underwent radiotherapy to attenuate 
tumor growth. On Days 25 and 27, the mice were imaged and treated with 5 Gy whole-
brain irradiation on the X-RAD SmART small animal irradiator (Precision X-Ray). A 
cone-beam CT was acquired for treatment planning, and irradiation was executed with 





All statistical analysis was conducted using GraphPad Prism 8 (GraphPad Software). 
All measurements are reported as the mean value ± standard deviation, and error 
bars in the figures represent standard deviation. N represents the sample size for each 
group as a single number or range of values. 
Median Survival Time: Kaplan-Meier analysis was used to compare the median 
survival of untreated (N = 102) and treated (N = 59) tumor-bearing mice. Specifically, 
the Mantel-Cox logrank test was used to test for significant differences between 
median survival times, and the logrank method was used to calculate the hazard ratio. 
In Vivo Tumor Volume Measurements: In untreated tumors during development, 
average volume at each time-point (N = 5-10) was compared with baseline average 
volume measured on Day 5 (N = 6). In treated tumors following radiotherapy, average 
volume at each time-point (N = 5-10) was compared with average volume at time of 
treatment on Day 26 (N = 8) as well as to maximum average volume (N = 10). Volume 
data was log-transformed to correct for heteroscedasticity and tested for significant 
differences using ordinary one-way ANOVA and follow-up Fisher’s Least Significant 
Differences tests (p < 0.05) where p is the probability value. 
Repeated measures of individual tumor volume values in treated tumor-bearing mice 
were further analyzed using mixed-effects analysis with the Geisser-Greenhouse 
correction as an additional check for significant changes.  
In Vivo Pyruvate-to-Lactate Measurements: During tumor development, average 
nLac of untreated tumors (N = 5) were compared with average nLac of controls  
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(N = 3) at each time-point. In treated tumors, average nLac at each time-point (N = 5-
8) was compared with average nLac at all prior time-points as well as to average nLac 
of untreated tumors and controls on Days 28 and 34. Statistical significance was 
determined using ordinary one-way ANOVA and follow-up Fisher’s Least Significant 
Difference tests (p < 0.05). 
Repeated measures of individual nLac values in treated tumor-bearing mice were 
further analyzed using mixed-effects analysis with the Geisser-Greenhouse correction 
as an additional check for significant changes.  
Ex Vivo Metabolite Pool Size Measurements: During tumor development, average 
metabolite pool sizes of untreated tumors (N = 5-7) were compared with average 
metabolite pool sizes of normal brain tissue controls (N = 3) at each time-point. In 
treated tumors, average metabolite pool sizes at each time-point (N = 5) were 
compared with average metabolite pool sizes at all prior time-points as well as to 
average metabolite pool sizes of untreated tumors and controls on Days 28 and 34. 
Statistical significance was determined using ordinary one-way ANOVA and follow-up 
Fisher’s Least Significant Difference tests. Due to the large number of comparisons 
(each set of comparisons made for 26 metabolites), the false discovery rate was 
controlled using the two-stage step-up method of Benjamini, Krieger and Yekutieli  
(Q < 0.05). 
Ex Vivo Protein Expression Measurements: During tumor development, average 
background-subtracted percent stained area (MCT1 and LDH-A) from 3 ROI in each 
40x capture (N = 1-5) from untreated tumors was compared at each time-point as well 
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as with healthy brain controls. Statistical significance was determined using ordinary 
one-way ANOVA and follow-up Fisher’s Least Significant Difference tests (p < 0.05).  
Inter-experiment Correlations: In the subset of mice in which anatomic MRI, 
hyperpolarized MRS, and NMR experiments were each performed at a particular time-
point, tumor volume, nLac, and metabolite pool sizes were directly correlated with one 
another. Pearson correlation coefficients were calculated for the following 
combinations: logarithm of tumor volume and nLac (N = 59), logarithm of tumor 
volume and metabolite pool sizes (N = 34), nLac and metabolite pool sizes (N = 47), 
and the individual metabolite pool sizes with one another (N = 70). R2 values were 
reported from these correlation coefficients and deemed statistically significant if  






Specific Aim 1: Track the Anatomic and Metabolic Evolution of GBM During Tumor 
Development 
Results 
Tumor Volume (in vivo): Following GSC implantation, average tumor volume was 
assessed every 3-4 days with T1-weighted, T2-weighted, and fluid-attenuated MRI 
(Fig 4.2). An initial baseline volume of 1.4 ± 0.5 mm3 was measured on Day 5. Average 
tumor volume experienced exponential growth (R2 = 0.60), increasing slowly at first 
before rapidly expanding on Day 21 where it nearly tripled from the prior time-point to 
a value of 15.2 ± 9.7 mm3. At a value of 3.5 ± 0.9 mm3, average tumor volume was 
significantly increased by Day 10 compared with baseline volume (p = 0.0282). By the 
endpoint of tumor development (Day 34), average untreated tumor volume was 88.6 
± 56.3 mm3. 
Hyperpolarized pyruvate-to-lactate conversion (in vivo): Using hyperpolarized 13C 
MRS, pyruvate-to-lactate conversion, quantified by nLac, was measured in tumor-
bearing mice and control mice every 7 days with an extra measurement on Day 10 to 
capture early tumor dynamics (Fig. 4.3). nLac is defined as the ratio of 
lactate/(lactate+pyruvate) where lactate and pyruvate are the area-under-the-curve 
values calculated from the time-resolved 13C spectra. Starting on Day 14, average 
nLac was significantly increased in tumor-bearing mice compared with control mice 
(0.39 ± 0.16 vs. 0.26 ± 0.10, p = 0.0273) which persisted throughout the remaining 
time-points in tumor development. In tumor-bearing mice, average nLac increased 
with a significantly nonzero slope (0.0069 days-1, p = 0.0006) to a final value of 0.45 
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± 0.09 on Day 34. In contrast, average nLac in control mice remained constant across 
all time-points (slope = 0.0005 days-1, p = 0.7674), at an average value of 0.26 ± 0.07.  
Metabolite pool size (ex vivo): Tumors and controls (healthy murine brain tissue) 
were excised at the same time-points as the hyperpolarized MRS experiments for ex 
vivo global metabolomics using NMR spectroscopy. Pool sizes of 26 metabolites were 
quantified and compared between tumors and controls in the same manner as nLac 
(Fig. 4.4, 4.5). By Day 28, average pool size of the metabolites alanine (3.92 ± 1.55 
vs. 1.54 ± 0.61 µM/mg, q = 0.0366) and phosphocholine (3.14 ± 1.62 vs. 1.32 ± 0.49 
µM/mg, q = 0.0491) were significantly increased in tumors compared with controls. On 
Day 34, average pool sizes of alanine (4.80 ± 1.98 vs. 1.45 ± 0.97 µM/mg, q = 0.0027) 
and phosphocholine (3.40 ± 1.23 vs. 1.17 ± 0.64 µM/mg, q = 0.0144) were still 
significantly increased in tumors compared with controls along with 
glycerophosphocholine (3.19 ± 1.14 vs. 0.93 ± 0.34 µM/mg, q = 0.0343), glycine 
(10.56 ± 6.53 vs. 2.86 ± 2.01 µM/mg, q = 0.0106), and valine (0.81 ± 0.43 vs. 0.28 ± 
0.20 µM/mg, q = 0.0072). 
Protein Expression (ex vivo): IHC was performed on ex vivo tumor samples at 
several time-points to measure changes in MCT1 and LDH-A expression throughout 
tumor development (Fig. 4.6). MCT1 is a membrane-bound protein responsible for 
shuttling monocarboxylates such as pyruvate into the cell. LDH-A is the enzyme 
responsible for converting intracellular pyruvate into lactate. Qualitatively, MCT1 was 
membrane-bound and LDH-A was confined to the cytoplasm, as expected. Semi-
quantitatively, average MCT1 percent stained area was significantly higher in 
untreated tumors by Day 21 compared with controls (13.43 ± 5.33 vs. 3.11 ± 3.57, p 
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= 0.0139; 13.43 ± 5.33 vs. 2.73 ± 1.98, p = 0.0110) and remained significantly 
increased through Days 25, 28, and 34. Additionally, average MCT1 percent stained 
area was significantly higher in untreated tumors by Day 21 compared with untreated 
tumors early in development on Day 10, (13.43 ± 5.33 vs. 5.15 ± 4.86, p = 0.0459) 
and remained significantly increased through Days 25, 28, and 34.  Conversely, 
average LDH-A percent stained area was elevated in untreated tumors at all time-
points of development, and the only significant increase was on Day 34 when 
compared with Days 14 (37.15 ± 5.48 vs. 19.77 ± 6.88, p = 0.0002), 25 (37.15 ± 5.48 





Figure 4.2: In vivo tumor volume significantly increases throughout tumor 
development. Average tumor volume, measured from anatomic MRI, is plotted as a 
function of time in untreated mice. An exponential function was fit to the data which is 
represented by the blue line. Error bars represent standard deviation (not visible 
before Day 21 due to scale of Y-axis). These values were log-transformed to correct 
for heteroscedasticity and tested for significant differences using ordinary one-way 
ANOVA and follow-up Fisher’s Least Significant Differences tests. Comparisons that 
produced p < 0.05 were deemed significant. *p < 0.05.  




Figure 4.3: In vivo pyruvate-to-lactate conversion significantly increases throughout 
tumor development. nLac values, measured with hyperpolarized 13C MRS, are plotted 
as a function of time for control mice (red circles) and untreated tumor-bearing mice 
(blue squares) during tumor development. Individual nLac values for each time-point 
are plotted in (A). Statistically significant changes of nLac between untreated tumor-
bearing and control mice for a particular time-point as well as between untreated 
tumor-bearing mice at different time-points are illustrated. Average nLac values 
between groups and time-points were assessed for significance using ordinary one-
way ANOVA and follow-up Fisher’s Least Significant Difference tests. Average nLac 
values for each time-point are plotted in (B) along with a linear fit of the data for 
untreated tumor-bearing mice and controls. The slopes of the linear fits are depicted 
in addition to the p-values from the comparisons of whether the slopes were 
significantly greater than zero as well as whether they were significantly different from 
each other. Linear regression was performed to calculate linear fits with each replicate 
considered, and slope values were tested for significance with the F-test (to test 
against a slope value of 0) or two-tailed T-test (to test the slope values against each 
other). Error bars represent standard deviation. Significance attributed to comparisons 







Figure 4.4: Ex vivo metabolite pool sizes significantly increase throughout tumor 
development (Part 1). Individual metabolite pool sizes, measured with NMR 
spectroscopy, are plotted as a function of time for control mice (red circles) and 
untreated mice (blue squares). Error bars represent standard deviation. The Y-axis is 
reported as concentration of metabolite pool per mg of tissue. Statistical significance 
was determined using ordinary one-way ANOVA and follow-up Fisher’s Least 
Significant Difference tests. The false discovery rate was controlled using the two-
stage step-up method of Benjamini, Krieger and Yekutieli, and significance was 






Figure 4.5: Ex vivo metabolite pool sizes significantly increase throughout tumor 
development (Part 2). Individual metabolite pool sizes, measured with NMR 
spectroscopy, are plotted as a function of time for control mice (red circles) and 
untreated mice (blue squares). Error bars represent standard deviation. The Y-axis is 
reported as concentration of metabolite pool per mg of tissue. Statistical significance 
was determined using ordinary one-way ANOVA and follow-up Fisher’s Least 
Significant Difference tests. The false discovery rate was controlled using the two-
stage step-up method of Benjamini, Krieger and Yekutieli, and significance was 








Figure 4.6: Ex vivo MCT1 expression significantly increases throughout tumor 
development. Histology stains of H&E, MCT1, and LDH-A were measured in ex vivo 
untreated tumor samples at several time-points throughout tumor development (A). It 
can be clearly seen that MCT1 is confined to the cell membrane and LDH-A to the 
cytoplasm. Percent stained area was calculated from the MCT1 (B) and LDH-A (C) 
IHC images at these time-points. Average percent stained area between time-points 
was assessed for significance using ordinary one-way ANOVA and follow-up Fisher’s 
Least Significant Difference tests with significance attributed to comparisons that 






Because average tumor volume values and their variances were low on Day 5, 
significant increases in untreated tumor volume were detected as soon as Day 10. 
However, it was not until Day 21 that average tumor volume began to rapidly increase, 
tripling in value compared with Day 18. Meanwhile, nLac was significantly increased 
compared with controls beginning on Day 14. Thus, hyperpolarized MRS predicted 
aggressive growth while the tumor was still in the slow-growing phase. One potential 
clinical application of this is the ability to distinguish aggressive tumors from their 
slower-growing counterparts early in tumor development and predict malignant 
transformation. This would allow physicians to begin administering therapy before the 
tumor aggressively invades neighboring tissue and is still treatable, which may lead 
to improvements in patient survival. 
An analysis of the REMBRANDT and TCGA databases of patient brain tumors 
revealed that SLC16A1 expression- the gene which encodes MCT1- was elevated in 
GBM compared with lower-grade astrocytoma, oligodendroma, and non-tumor brain 
samples 128. When grouping these glioma subtypes together, those with high 
expression of SLC16A1 led to significantly reduced survival compared to those with 
low expression of SLC16A1 129. Further analysis of the TCGA database revealed that 
MCT1 expression was significantly reduced in IDH1-mutant glioma samples 
compared to those with wild-type IDH1 130. IDH1 mutations are predominately found 
in WHO grade II and III gliomas (70% of cases) compared to grade IV GBM (12% of 
cases), and GBM which harbor the IDH1 mutation lead to significantly longer survival 
times of greater than two-fold 32,131. In individual studies, MCT1 immunoreactivity 
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scores were significantly increased in 24 high-grade patient samples of GBM and 
anaplastic astrocytoma compared with 24 low-grade patient samples of 
oligodendrogliomas and low-grade astrocytomas 132, and it was significantly increased 
in 78 GBM patient samples compared with 24 non-tumor brain samples 133. 
Furthermore, the MCT inhibitor α-cyano-4-hydroxycinnamate (CHC) induced cytotoxic 
effects and inhibited proliferation, invasion, and migration capacity in high-grade 
glioma cell lines which possessed high expression of MCT1 133,134. Because MCT1 
has differential expression between malignant and healthy brain cells, and even 
between low- and high-grade disease, it is an attractive prognostic biomarker. In this 
study, we have shown that increasing MCT1 expression correlates with 
hyperpolarized pyruvate-to-lactate conversion throughout GBM tumor development. 
In patients with prostate 135 and breast cancers 136, similar correlations of MCT1 
expression and hyperpolarized pyruvate-to-lactate conversion were observed which 
also correlated with tumor grade. Thus, hyperpolarized MRS has a promising clinical 
application in the early detection of high-grade brain cancer through MCT1 






Specific Aim 2: Administer Radiation Therapy to GBM And Measure the Anatomic and 
Metabolic Response During Tumor Regression 
Results 
Tumor Volume (in vivo): Following radiotherapy, tumor volume was measured on 
Days 26, 30, 34, and every 7 days thereafter (Fig. 4.7). On Day 34, average treated 
tumor volume was significantly increased compared with its initial value on Day 26 
(82.9 ± 66.6 vs. 26.0 ± 14.9 mm3, p = 0.0090). Average treated tumor volume then 
began to decrease to a minimum of 57.3 ± 51.2 mm3 on Day 48 although no significant 
differences were observed compared with initial treated tumor volume on Day 26 or 
maximum treated tumor volume on Day 34. 
Hyperpolarized pyruvate-to-lactate conversion (in vivo): Following radiotherapy, 
hyperpolarized MRS experiments were conducted in treated mice starting on Day 28 
and every 7 days thereafter (Fig. 4.8). Average nLac decreased following radiotherapy 
and was significantly decreased in treated tumor-bearing mice on Day 48 compared 
with treated tumor-bearing mice on Days 28 (0.31 ± 0.05 vs. 0.44 ± 0.09, p = 0.0080), 
34 (0.31 ± 0.05 vs. 0.49 ± 0.08, p = 0.0004), and 41 (0.31 ± 0.05 vs. 0.43 ± 0.07, p = 
0.0186). Additionally, average nLac was significantly decreased in treated tumor-
bearing mice on Day 48 compared with untreated tumor-bearing mice on Days 28 
(0.31 ± 0.05 vs. 0.48 ± 0.06, p = 0.0008) and 34 (0.31 ± 0.05 vs. 0.45 ± 0.09, p = 
0.0063).  Lastly, of the tumor-bearing mice which had initial values of nLac < 0.4 
immediately following treatment (on Day 28 or 34), 0/3 died from tumor burden by the 
Day 94 endpoint of the study. In contrast, 5/7 treated tumor-bearing mice with initial 
values of nLac > 0.4 died from tumor burden before reaching the Day 94 endpoint. 
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Metabolite pool size (ex vivo): Following radiotherapy, samples were excised from 
treated mice at the same time-points as the hyperpolarized MRS experiments for NMR 
spectroscopy (Fig. 4.9, 4.10). On Day 34, average pool size of the following 
metabolites were significantly decreased in treated tumors compared with untreated 
tumors: alanine (2.20 ± 1.42 vs. 4.80 ± 1.98 µM/mg, q = 0.0072), glycine (5.21 ± 4.23 
vs. 10.56 ± 6.53 µM/mg, q = 0.0457), and valine (0.34 ± 0.18 vs. 0.81 ± 0.43 µM/mg, 
q = 0.0061). By Day 48, average pool size of these metabolites were still significantly 
decreased in treated tumors compared with untreated tumors on Day 34 along with 
the metabolites, NAD+ (0.36 ± 0.05 vs. 0.69 ± 0.21 µM/mg, q = 0.0496) and 
phosphocholine (1.80 ± 0.79 vs. 3.40 ± 1.23 µM/mg, q = 0.0457). Another result of 
note is that on Day 28, average glutathione pool size was significantly increased in 
treated tumors compared with treated tumors on Days 41 (5.32 ± 1.79 vs. 1.50 ± 0.58 





Figure 4.7: In vivo tumor volume does not significantly decrease throughout 
regression. Average tumor volume, measured from anatomic MRI, is plotted as a 
function of time in treated mice. Apparent pseudoprogression was observed 
immediately following radiotherapy before tumor volume began to decrease. Error 
bars represent standard deviation. These values were log-transformed to correct for 
heteroscedasticity and tested for significant differences using ordinary one-way 
ANOVA and follow-up Fisher’s Least Significant Differences tests. Comparisons that 







Figure 4.8: In vivo pyruvate-to-lactate conversion significantly decreases throughout 
tumor regression. Individual nLac values, measured with hyperpolarized 13C MRS, are 
plotted as a function of time for untreated (blue squares) and treated (green triangles) 
tumor-bearing mice during tumor regression following radiotherapy. Average nLac 
values between groups and time-points were assessed for significance using ordinary 
one-way ANOVA and follow-up Fisher’s Least Significant Difference tests. Error bars 
represent standard deviation. Significance attributed to comparisons that produced  






Figure 4.9: Ex vivo metabolite pool sizes significantly decrease throughout tumor 
regression (Part 1). Individual metabolite pool sizes, measured with NMR 
spectroscopy, are plotted as a function of time for untreated (blue squares) and treated 
(green triangles) tumor-bearing mice. Error bars represent standard deviation. The Y-
axis is reported as concentration of metabolite pool per mg of tissue. Statistical 
significance was determined using ordinary one-way ANOVA and follow-up Fisher’s 
Least Significant Difference tests. The false discovery rate was controlled using the 
two-stage step-up method of Benjamini, Krieger and Yekutieli, and significance was 





Figure 4.10: Ex vivo metabolite pool sizes significantly decrease throughout tumor 
regression (Part 2). Individual metabolite pool sizes, measured with NMR 
spectroscopy, are plotted as a function of time for untreated (blue squares) and treated 
(green triangles) tumor-bearing mice. Error bars represent standard deviation. The Y-
axis is reported as concentration of metabolite pool per mg of tissue. Statistical 
significance was determined using ordinary one-way ANOVA and follow-up Fisher’s 
Least Significant Difference tests. The false discovery rate was controlled using the 
two-stage step-up method of Benjamini, Krieger and Yekutieli, and significance was 





One current clinical challenge facing neuro-oncologists is distinguishing 
pseudoprogression from true progression following radiotherapy. Pseudoprogression 
is an anatomic MRI pattern that mimics tumor progression and can confound 
treatment monitoring with direct consequences in clinical practice. It can lead to 
prematurely withholding adjuvant temozolomide or continuing with potentially 
ineffective treatment in patients in which cases of tumor progression are not clear 137. 
Apparent pseudoprogression was observed in this study with anatomic MRI as tumor 
volumes in treated mice significantly increased on Days 34 and 41 before eventually 
decreasing throughout regression. Conversely, there were no significant increases in 
nLac during this time-course, which suggests hyperpolarized MR could help mitigate 
this problem in the clinic.  
When comparing the quality of the data, there were larger magnitudes of 
change and lower variance in the hyperpolarized MRS data compared with the 
anatomic MRI data throughout tumor regression. This allowed us to observe 
significant changes in hyperpolarized pyruvate-to-lactate conversion following 
radiotherapy, rendering it a more sensitive measure of tumor response. After 
radiotherapy, nLac decreased significantly in treated tumor-bearing mice on Day 48 
compared with Days 28 and 34 whereas tumor volume did not significantly decrease 
in this time period. This suggests that hyperpolarized MRS has the potential to 
effectively detect treatment response of GBM to radiotherapy and do so more reliably 
than measuring changes in tumor volume with anatomic MRI. Furthermore, the 
predictive value of hyperpolarized MRS to stratify subjects into likely and unlikely 
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responders was alluded to when looking at the initial nLac values following treatment. 
Of the 10 mice who underwent hyperpolarized MRS immediately following treatment, 
a cutoff value of nLac > 0.4 was able to predict if a mouse would succumb to tumor 
burden before the Day 94 endpoint with a sensitivity of 100% and specificity of 60%. 
These sample sizes are too small to draw definite conclusions, but it serves as 







Specific Aim 3: Monitor the Anatomic and Metabolic States of Regressed GBM 
Tumors to the Point of Relapse 
Results 
Tumor Volume (in vivo): The same group of mice were imaged every 7 days 
throughout tumor recurrence (Fig. 4.11). After reaching a minimum of 57.3 ± 51.2 mm3 
on Day 48, average treated tumor volume monotonically increased to a final volume 
of 72.3 ± 57.0 mm3 on Day 72. While this value was significantly higher than initial 
treated tumor volume on Day 26 (p = 0.0396), neither grouped ANOVA analysis nor 
mixed-effects analysis of individual repeated measures revealed any significant 
increases in treated tumor volume throughout the stage of tumor recurrence. 
Hyperpolarized pyruvate-to-lactate conversion (in vivo): Hyperpolarized MRS 
experiments were performed on the same group of mice every 7 days throughout 
tumor recurrence (Fig. 4.12). Average nLac linearly increased with a significantly 
nonzero slope (0.0067 days-1, p < 0.0001) in treated tumor-bearing mice from Day 48 
to Day 68. When compared with the trend of average nLac in untreated tumor-bearing 
mice during tumor development, average nLac in treated tumor-bearing mice during 
tumor recurrence had a nearly identical slope (0.0067 vs. 0.0069 days-1, p = 0.9415). 
When analyzed with grouped ANOVA analysis, average nLac in treated tumor-bearing 
mice was significantly increased by Day 68 compared with treated tumor-bearing mice 
on Days 48 (0.44 ± 0.04 vs. 0.31 ± 0.05, p = 0.0085) and 55 (0.44 ± 0.04 vs. 0.35 ± 
0.05, p = 0.0452) as well as when compared with control mice on Days 28 (0.44 ± 
0.04 vs. 0.32 ± 0.10, p = 0.0341) and 34 (0.44 ± 0.04 vs. 0.22 ± 0.01, p = 0.0002). 
Furthermore, when analyzing comparisons of individual repeated measurements with 
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mixed-effects analysis, nLac was still significantly increased on Day 68 compared with 






Figure 4.11: In vivo tumor volume does not significantly increase throughout 
recurrence. Average tumor volume, measured from anatomic MRI, is plotted as a 
function of time in treated mice. Error bars represent standard deviation. These values 
were log-transformed to correct for heteroscedasticity and tested for significant 
differences using ordinary one-way ANOVA and follow-up Fisher’s Least Significant 






Figure 4.12: In vivo pyruvate-to-lactate conversion significantly increases throughout 
tumor recurrence. nLac values, measured with hyperpolarized 13C MRS, are plotted 
as a function of time for untreated (blue squares) and recurring treated (green 
triangles) tumor-bearing mice during tumor recurrence. Individual nLac values for 
each time-point are plotted in (A). Statistically significant changes of nLac between 
treated tumor-bearing mice at different time-points are illustrated. Average nLac 
values between time-points were assessed for significance using ordinary one-way 
ANOVA and follow-up Fisher’s Least Significant Difference tests. Average nLac 
values for each time-point are plotted in (B) along with a linear fit of the data for 
untreated and recurring treated tumor-bearing mice, which demonstrates the similarity 
of nLac evolution over time. The slopes of the linear fits are depicted in addition to the 
p-values from the comparisons of whether the slopes were significantly greater than 
zero as well as whether they were significantly different from each other. Linear 
regression was performed to calculate linear fits with each replicate considered, and 
slope values were tested for significance with the F-test (to test against a slope value 
of 0) or two-tailed T-test (to test the slope values against each other). Error bars 
represent standard deviation. Significance attributed to comparisons that produced p 







To our knowledge, this is the first study to investigate all three stages of brain 
tumor progression, including tumor recurrence, with hyperpolarized MRS. There is 
one prior study that used hyperpolarized MRSI to measure the glycolytic effects of 
switching off MYC expression in transgenic mouse models of breast cancer which 
resulted in tumor regression followed by recurrence 138. Shin, et al. observed that the 
hyperpolarized lactate/pyruvate ratio significantly decreased as the tumors regressed 
from MYC withdrawal, and after a latency period, the tumors recurred, which was 
accompanied by a significant increase of hyperpolarized lactate/pyruvate ratio. In one 
of the mice, this increase of lactate production was observed prior to increases in 
tumor volume, which supports the results we observed across multiple treated GBM 
tumor-bearing mice.  
Analogous with the tumor regression stage, no significant changes in volume 
were observed during tumor recurrence. The only significant change in volume that 
was observed following radiotherapy was that average treated tumor volume on Day 
72 was significantly increased compared with initial treatment volume on Day 26, 
which does suggest that the mice were beginning to relapse. Even when treated tumor 
volumes were normalized to their individual initial values to measure percent change 
(for those mice that were measured several times throughout regression and 
recurrence), no significant changes were observed throughout regression or 
recurrence (Fig. 4.13). Within this set of repeated tumor volume measurements, 
average tumor volume reached a minimum of 81% of its initial treated volume on Day 
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62 before increasing back to 96% of its initial treated volume on Day 72, which further 
suggests that relapse was beginning to occur.  
Hyperpolarized MRS was effective at predicting relapse as nLac was 
significantly increased in treated mice by Day 68 compared with Days 48 and 55 
whereas tumor volume did not significantly increase in this time period. Furthermore, 
nLac values in treated mice on Day 68 were equivalent to initial values following 
treatment on Days 28 and 34. Thus, there was a complete reprise in hyperpolarized 
pyruvate-to-lactate conversion by Day 68, further supporting that relapse was 
occurring. When looking at percent change of nLac in the mice that were measured 
at multiple time-points throughout regression and recurrence, average nLac fell to a 
minimum of 71% of its initial value after treatment on Day 55. This value was 
significantly decreased (p = 0.0258) compared with Day 68 when average nLac was 
back to 88% of the initial treated value (Fig. 4.13). Based on these data, we suspect 
that pyruvate-to-lactate conversion measured with hyperpolarized MRS in this animal 
model is a direct metabolic readout of tumor response during regression (Day 55) and 
relapse (Day 68) which is occurring prior to radiological tumor volume changes.  
Another interesting result is that the slope of nLac in treated tumor-bearing mice 
in the tumor recurrence stage was nearly identical to that of the untreated tumor-
bearing mice in the development stage. This suggests that the metabolic programming 
of recurring tumors was not altered, and the mechanism of recurrence was similar to 
that of initial growth. This is expected since tumors were only treated with 
radiotherapy. Had adjuvant chemotherapy or targeted therapy been implemented, 
cancer cells could have potentially been pressured to escape therapy through the 
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development of resistance by adapting and reprogramming a new mechanism of 
survival and proliferation, which may have been reflected in the metabolic assays. 
This idea is currently of immense interest as metabolic changes that reflect resistance 
to therapy could be exploited with molecular imaging techniques and would be 
invaluable to physicians looking to optimize therapeutic approaches. This could have 
a significant benefit for patients with recurrent disease, and future research will 
investigate this idea further.  
Because tumor volume appeared to lag behind hyperpolarized pyruvate-to-
lactate conversion, it was postulated that the metabolic events would more accurately 
align with the rate of change of volume. After all, macroscopic tumor volume is a result 
of the culmination of all the growth processes occurring in the cell. Increased pyruvate-
to-lactate conversion, which is a biomarker of proliferation, should be associated with 
relative increases in volume rather than the absolute value of the volume. Therefore, 
the volume curves were linearly interpolated between the data points to form a 
continuous curve and then numerically differentiated, using the symmetric Newton’s 
quotient method, to calculate the rate of change of the volume (dVolume/dt) over time 
(Fig. 4.14). The timing of the shift from regression to recurrence appears to be more 
consistent between nLac and dVolume compared with nLac and volume, although 





Figure 4.13: Percent change of nLac, but not tumor volume, is significantly altered 
during tumor regression and recurrence. Repeated measures of tumor volume are 
acquired over time in treated mice with anatomic MRI (A) and hyperpolarized MRS 
(B). At each time-point, volume and nLac were normalized to their initial value 
following treatment and plotted as percent change over time (C). The data were tested 
for significance using mixed-effects analysis with the Geisser-Greenhouse correction, 
and comparisons that produced p < 0.05 were deemed significant. *p < 0.05,  






Figure 4.14: Evolution of nLac, volume, and rate of change of volume following 
radiotherapy. nLac (solid lines) and tumor volume (dashed lines) are plotted on the 
same time axis (represented as weeks after treatment) to clearly compare the 
changes in these variables over time (A). Tumor volume was numerically 
differentiated using the symmetric Newton’s quotient method and plotted over time to 
visualize the rate of change of volume (B). A dashed line is drawn through dVolume/dt 
= 0 to illustrate at what value tumor volume is not changing. Values below this line 
indicate tumors are shrinking and values above this line indicate that they are growing. 











Radiotherapy Significantly Extends Survival of GSC 8-11 Tumor-Bearing Mice: 
In mice implanted with GSC 8-11, survival time was compared between untreated 
mice and mice treated with 2x5 Gy of whole-brain irradiation on Days 25 and 27 using 
Kaplan-Meier analysis (Fig. 4.15). Median survival was significantly increased in 
treated tumor-bearing mice compared with untreated mice (88 vs. 34 days, p < 
0.0001). There was over a 250% increase in median survival time, which produced a 
hazard ratio of 4.6. Therefore, the radiotherapy dose of 2x5 Gy was effective at 
extending the survival of tumor-bearing mice, allowing for tumor regression and 
recurrence to be assessed in the radiotherapy treated mouse cohort.   
Anatomic and Metabolic Changes Throughout All of Tumor Progression (Day 1-
72): Tumor volume (Fig. 4.16), hyperpolarized pyruvate-to-lactate (Fig. 4.17), and 
metabolite pool size (Fig. 4.18, 4.19) data from each stage of tumor progression 
(development, regression, and recurrence) are combined and plotted on one graph. 
The purpose of these figures is to qualitatively visualize the complete evolution of 
tumor anatomy and metabolism, so statistical analyses are not included (since they 
were presented in the previous sections). Refer to Table 4.1 for all significant 
metabolite pool size changes throughout tumor development and regression. 
Correlations Between Tumor Volume, In Vivo Pyruvate-To-Lactate Conversion, 
And Ex Vivo Metabolite Pool Sizes: Log-transformed tumor volume and nLac values 
from the same mice at the same time-points were plotted against one another, and 
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significant positive correlations were observed in untreated (R2 = 0.3086, p = 0.0021) 
and treated (R2 = 0.2076, p = 0.0100) tumor-bearing mice (Fig. 4.20A). Of the ex vivo 
metabolite pools that were significantly altered during tumor development or 
regression, those that were significantly positive-correlated with log-transformed 
tumor volume in untreated tumors were (Fig. 4.20B, Fig. 4.21): alanine (R2 = 0.6821, 
p < 0.0001), glycerophosphocholine (R2 = 0.5001, p = 0.0001), glycine (R2 = 0.5626, 
p < 0.0001), NAD+ (R2 = 0.3224, p = 0.0038), phosphocholine (R2 = 0.5528, p < 
0.0001), phosphoethanolamine (R2 = 0.5515, p < 0.0001), and valine (R2 = 0.4958, p 
= 0.0001). Significant positive correlations were also observed between nLac and ex 
vivo pool size of glycerophosphocholine (R2 = 0.3315, p = 0.0032) and 
phosphoethanolamine (R2 = 0.1802, p = 0.0387) (Fig. 4.20C,D). Other than a negative 
correlation between NAD+ pool size and nLac (R2 = 0.40, p = 0.0497), no significant 
correlations between ex vivo metabolite pool sizes and either log-transformed tumor 
volume or in vivo pyruvate-to-lactate conversion were observed in treated tumors. 
Pearson correlation coefficients were also calculated between each of the ex vivo 
metabolite pool sizes in the untreated and treated tumors, controls, and combination 
of all groups. Correlation matrices of these values are illustrated for qualitative 
analysis of potential metabolic pathways that could be up- or down-regulated during 





Figure 4.15: Radiotherapy significantly extends survival of GSC 8-11 tumor-bearing 
mice. Median survival of treated mice (green line) was significantly higher compared 
with untreated mice (blue line) (88 vs. 34 days, p < 0.0001). The hazard ratio of 
untreated-to-treated mice was 4.6. Mice that were euthanized on specific time-points 
for ex vivo experiments as well as those that died from non-tumor-related causes 
(such as from infection or from the experiment itself) were censored (black markers). 
Survival was calculated using Kaplan-Meier analysis. Significant differences between 
the curves was calculated with the Mantel-Cox logrank test and the hazard ratio using 




Figure 4.16: Tumor volume increases during development but does not significantly 
change throughout regression or recurrence. Average tumor volume, measured from 
anatomic MRI, is plotted as a function of time in untreated (blue squares) and treated 






Figure 4.17: In vivo pyruvate-to-lactate conversion is significantly altered throughout 
tumor development, regression, and recurrence. Individual nLac values, measured 
with hyperpolarized 13C MRS, are plotted as a function of time for control mice (red 
circles) and untreated (blue squares) and treated (green triangles) tumor-bearing mice 






Figure 4.18: Ex vivo metabolite pool sizes are significantly altered throughout tumor 
development and regression (Part 1). Individual metabolite pool sizes, measured with 
NMR spectroscopy, are plotted as a function of time for control mice (red circles) and 
untreated (blue squares) and treated (green triangles) tumor-bearing mice. Error bars 






Figure 4.19: Ex vivo metabolite pool sizes are significantly altered throughout tumor 
development and regression (Part 1). Individual metabolite pool sizes, measured with 
NMR spectroscopy, are plotted as a function of time for control mice (red circles) and 
untreated (blue squares) and treated (green triangles) tumor-bearing mice. Error bars 





Metabolite Tumor Development Tumor Regression Potential Pathway 
Valine U34 > C34, q=0.0072 
T34 < U34, q=0.0061 
T41 < U34, q=0.0013 
T48 < U34, q=0.0027 
BCAA Catabolism 
Alanine U28 > C28, q=0.0366 U34 > C34, q=0.0027 
T34 < U34, q=0.0072 
T41 < U28, q=0.0063 
T41 < U34, q=0.0004 
T48 < U28, q=0.0149 
T48 < U34, q=0.0011 
Glutamine 
Anaplerosis 
Glycine U34 > C34, q=0.0106 
T34 < U34, q=0.0457 
T41 < U34, q=0.0034 
T48 < U34, q=0.0021 
Glycine Cleavage  
 
Folate Cycle  
Phosphocholine U28 > C28, q=0.0491 U34 > C34, q=0.0144 
T41 < U28, q=0.0284 
T41 < U34, q=0.0106 





phosphocholine U34 > C34, q=0.0343  
Phosphoethanolamine  
T41 < U28, q=0.0154 
T41 < U34, q=0.0496 
T48 < U28, q=0.0401 
Glutathione  T41 < T28, q=0.0328 T48 < T28, q=0.0491 
Trans-Sulphuration 
Pathway 
NAD+  T41 < U34, q=0.0106 T48 < U34, q=0.0496 Energy Metabolism 
 
Table 4.1: List of significantly altered metabolites during tumor development and/or 
tumor regression. In the “Tumor Development” and “Tumor Regression” columns, the 
naming convention is the group (U=untreated, C=control, T=treated) followed by the 
time-point. For example, U34 > C34, q=0.0241 indicates that the metabolite was 
significantly increased in untreated tumor-bearing mice on Day 34 compared with 
control mice on Day 34, and the comparison produced a q-value of 0.0241. The q-
values are p-values adjusted to control the false discovery rate using the two-stage 
step-up method of Benjamini, Krieger and Yekutieli. Pathways that the metabolites 




Figure 4.20: Signficant correlations were observed between tumor volume, in vivo 
pyruvate-to-lactate conversion, and ex vivo metabolite pool sizes. The log-
transformed tumor volume and nLac measurements from the same mice at the same 
time-points were plotted against each other and produced signficant correlations in 
both groups of untreated and treated tumor-bearing mice (A). The log-transformed 
tumor volume values were also plot against metabolite pool sizes from the same mice 
at the same time-points which produced signficant correlations with 
glycerophosphocholine among other metabolites (B) in untreated tumors. nLac values 
were then plotted against the metabolite pool sizes in the same mice at the same time-
points, and significant correlations between nLac and glycerophosphocholine (C) and 
phosphoethanolamine (D) were observed in untreated tumors. Correlation was 
determined by calculating Pearson correlation coeffeicients and signficance was 






R2 = 0.3086, p = 0.0021 
R2 = 0.2076, p = 0.0100 
R2 = 0.3315, p = 0.0032 R2 = 0.1802, p = 0.0387 




Figure 4.21: Ex vivo metabolite pool sizes are significantly correlated with tumor 
volume. Average metabolite pool sizes, measured from NMR spectroscopy, are 
plotted as a function of tumor volume in untreated (blue squares) and treated (green 
triangles) tumor-bearing mice. Correlation was determined by calculating Pearson 
correlation coeffeicients and signficance was attributed to correlations that produced 




Figure 4.22: Correlations were observed between individual ex vivo metabolite pool 
sizes. Correlation matrices were created to visualize Pearson correlation coefficients 
between each of the metabolite pool sizes in untreated tumors (A), treated tumors (B), 
healthy brain controls (C), and all groups combined (D). Correlations between these 
metabolite pool sizes could inform on specific metabolic pathways which are up- or 








These findings demonstrate that in situ analysis of metabolic changes linking 
the stages of tumor progression (tumor development, regression following 
radiotherapy, and recurrence) using hyperpolarized MRI and NMR spectroscopy is 
feasible and  informative. By acquiring each of these measurements, along with 
anatomic growth, in the same mice and at multiple common time-points, the individual 
evolution of the results from these assays were investigated as well as their 
relationship and correlation with one another. Thus, an extensive evaluation of cancer 
metabolism as it advances through different stages of tumor progression was 
examined. The mouse model used in this project is an orthotopic implantation of 
patient-derived GBM (GSC 8-11), which generates confidence that these results are 
clinically relevant and potentially translatable. However, we do acknowledge the 
caveat that host immunity is not fully represented in these models, which could 
potentially impact tumor growth, response to therapy, and metabolism.  
The results from the hyperpolarized MRS experiments illustrate that 
measurements of pyruvate-to-lactate conversion are variable in all stages of tumor 
progression. Therefore, when researchers are using this technique to compare 
hyperpolarized pyruvate-to-lactate values between tumor types of varying growth 
rates or before and after treatment, the stage of tumor progression needs to be 
considered. Factors that could influence the production of hyperpolarized lactate in 
these experiments include number of cancer cells in the ROI, vascularity of the tumor, 
concentration of intracellular lactate, concentration of membrane pyruvate 
transporters such as MCT1, concentration of intracellular LDH-A, and concentration 
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of cofactor NADH. The number of cancer cells in the ROI is roughly estimated by the 
observable tumor volume, and there was a significant correlation of nLac with tumor 
volume in both untreated and treated tumor-bearing mice. However, only a subset of 
the total number of cancer cells are accounted for in tumor volume measurements. 
Limits in hardware resolution and SNR lead to inaccuracies of complete tumor 
segmentation as well as inter-observer variability. Additionally, GBM tumors are 
invasive and often produce microscopic satellite lesions and quiescent cells that are 
not detectable with current MRI techniques 139. Lack of tumor vascularity can inhibit 
the influx of hyperpolarized pyruvate in the ROI, producing noisy spectra. In our 
hyperpolarization experiments, average maximum pyruvate SNR was nearly 7000 
and was routinely over 1000. Thus, these tumors appeared to be well-vascularized.  
We believe that the increased MCT1 expression observed in this study 
contributed to the increased pyruvate-to-lactate conversion seen throughout tumor 
development. Recently, we have demonstrated that after delivery of [1-13C]pyruvate 
to the extracellular space of the tumor, pyruvate transport, primarily driven by MCT1, 
is a key variable and often rate-limiting in these hyperpolarized pyruvate MR 
experiments in the context of pancreatic tumors 140, and there have been additional 
reports of correlations of MCT1 expression and pyruvate-to-lactate conversion in GBM 
95 and breast cancer 136. In contrast, the only significant increase of LDH-A expression 
was observed at the final time-point of tumor development on Day 34. Ex vivo lactate 
pool size in the GSC 8-11 tumors from NMR experiments did not reveal significant 
changes over the course of tumor progression. Additionally, neither untreated nor 
treated tumors produced significant correlations between their in vivo nLac values with 
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ex vivo lactate pool sizes, although we have observed this correlation in patient-
derived pancreatic cancer mouse models of increasing aggressiveness 122.  
In addition to probing changes in glycolytic metabolism, we were also interested 
in identifying alternate metabolic pathways which were potentially deregulated 
throughout tumor progression. These could serve as leads for subsequent imaging 
probes and therapeutic targets. Results from the NMR experiments of the ex vivo 
tissue samples demonstrated that amino acid metabolism was significantly altered 
throughout tumor progression. These metabolites are essential for protein synthesis 
and are necessary for cellular growth and division. In particular, the pool sizes of 
valine, alanine, and glycine were significantly increased by the end of tumor 
development and decreased following radiotherapy. These amino acids were also 
significantly correlated with tumor volume in untreated mice. Valine is a branched 
chain amino acid (BCAA) and can be used for protein synthesis or oxidized for energy 
production. Branched-chain aminotransferase 1 (BCAT1) generates glutamate during 
BCAA catabolism and is overexpressed in many cancers including glioma 141–144. 
Alanine and α-ketoglutarate can be reversibly produced from pyruvate and glutamate 
through alanine transaminase (ALT) whenever the pyruvate substrate is available. In 
some hyperpolarized [1-13C]pyruvate MR experiments, it is possible to observe 
hyperpolarized alanine production, and a decreasing ratio of hyperpolarized alanine-
to-lactate has been suggested as a biomarker of disease progression in pancreatic 
cancer 145,146. Unfortunately, we could not reliably observe hyperpolarized alanine in 
our experiments to suggest the same is true for GBM. Increased glutamine 
anaplerosis via ALT has been linked to the viability and proliferation of brain 147,  
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breast 148,149, colorectal 150, and prostate 151 cancers. It was recently demonstrated 
that alanine uptake and utilization through the SLC38A2 membrane transporter played 
a key role in pancreatic cancer metabolism and proliferation 152. Glycine is derived 
from serine in one-carbon metabolism to maintain redox balance through antioxidant 
production such as glutathione as well as to produce metabolites involved in purine 
nucleotide and lipid synthesis, all of which are important for cancer survival and 
proliferation 153. Glycine production through serine hydroxymethyltransferase (SHMT)- 
a transcriptional target of c-Myc 154- has been implicated as a driver of cancer cell 
proliferation in glioma 155 and many other types of tumors 156–160.  
Many tumors rely on antioxidants to quench the effects of reactive oxygen 
species (ROS) produced from treatments such as radiotherapy and chemotherapy 161 
as well as oxidative stress from increased energy metabolism 162. This is often seen 
through an increased production of NADPH and glutathione through the pentose 
phosphate pathway and one-carbon metabolism 163. We observed a significant 
increase in ex vivo glutathione pool size in treated tumors one day following 
radiotherapy compared with treated tumors further into regression, which we believe 
is an acute response to increased ROS generated from radiotherapy. Increased 
concentration of antioxidants such as glutathione in tumors immediately following 
treatment has also been reported elsewhere 164,165.  
Increased phospholipid metabolism was observed in these GBM tumors 
compared with normal brain tissue and correlated with progression. The Kennedy 
pathway describes the phosphorylation of choline and ethanolamine to 
phosphocholine and phosphoethanolamine, which eventually form 
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phosphatidylcholine and phosphatidylethanolamine 166. These are the two most 
abundant phospholipids in the cell membrane. The second messenger diacylglycerol 
is produced in this pathway which can further activate downstream signaling for 
cellular growth and fatty acid oxidation 167. Phosphatidylcholine can be broken down 
into glycerophosphocholine for storage and eventually converted back into choline. 
Increased phosphocholine and choline-containing metabolite concentrations have 
been observed in gliomas 147,168–171 and many other types of cancer 40,172,173, so it was 
not surprising to see significantly elevated pools of these metabolites, along with 
phosphoethanolamine in untreated tumors compared with controls and treated 
tumors. Furthermore, in untreated tumors, tumor volume was significantly correlated 
with phosphoethanolamine, phosphocholine, and glycerophosphocholine, and 
hyperpolarized pyruvate-to-lactate conversion was significantly correlated with 
phosphoethanolamine and glycerophosphocholine.   
Nicotinamide adenine dinucleotide (NAD+) is an important cofactor in cellular 
metabolism and is necessary for glycolysis, pyruvate-to-lactate conversion, and serine 
biosynthesis. Nicotinamide phosphoribosyltransferase (NAMPT) is the main enzyme 
for NAD+ biosynthesis and has been found to be upregulated in several cancers 
including glioma 174,175. Inhibition of this enzyme leads to antitumoral effects, which 
has led to the development of drugs for different types of cancer 176–180. We observed 
a significant correlation of NAD+ pool size with tumor volume in untreated tumors and 
a significant decrease in NAD+ levels following treatment. 
Collectively, several clinical deliverables were discussed in this study which 
have the potential to be implemented throughout the patient care pipeline. With 
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hyperpolarized MR, these include the ability to predict whether a tumor will be slow-
growing or aggressive at the time of diagnosis, help discriminate pseudoprogression 
from true progression and predict whether patient survival will be improved shortly 
after administration of a treatment, and determine whether the patient is on the verge 
of relapse during a follow-up exam. Each of these scenarios would give physicians 
the time to take appropriate interventional action, improving the chances of patient 
survival. Additionally, we have demonstrated that ex vivo metabolite pool size data 
from NMR spectroscopy experiments varies with stage of tumor progression 
(particularly amino acid and phospholipid metabolism). These data can be combined 
with in vivo hyperpolarized MR data to build a model based on tumor metabolism to 
predict clinical outcomes. Because these data are orthogonal (with hyperpolarized MR 
measuring real-time flux and NMR spectroscopy measuring metabolite pool size), this 
model should be more predictive than either technique alone. Unfortunately, we could 
not implement this in our study because the tumor excision process for NMR 
spectroscopy requires euthanasia of the mice, preventing validation of treatment 
response or survival outcomes. However, in the clinical setting, biopsies of tumor 
tissue can be obtained during diagnosis as well as post-surgery, which could then be 
processed for NMR spectroscopy. Combining this data with hyperpolarized MR 
acquisitions at these time-points to predict clinical outcomes could form the basis for 





SUPPLEMENTAL DATA: PROFILING IMMUNOMETABOLISM  
Introduction 
While the role of the immune system is well-understood when it comes to most 
bacterial and viral infections, it is less clear where it fits in the context of cancer 181. By 
1960, Sir Macfarlane Burnet and Lewis Thomas proposed the theory of cancer 
immunosurveillance which stated that one primary role of the immune system was to 
maintain tissue homeostasis by recognizing small groups of tumor cells by their newly 
presenting antigens and removing them before they present clinically 182,183. Ideally, 
natural killer (NK) cells, CD8+ cytotoxic T-cells, and CD4+ helper T-cells eradicate 
abnormally behaving cells through interferon-γ and other cytotoxins 184. While a 
functioning immune system does reduce the risk of cancer 185, it is not capable of 
preventing all cases, and it can even be co-opted to promote the formation of tumors 
and progression to late-stage metastatic cancer 186. It has been suggested that the 
combination of genomic instability and immunoediting, which involves the selection 
pressure for non-immunogenic cells, is what allows some tumors to survive and thrive 
amongst an otherwise functioning immune system 187.  
Because cancer originates from normal, healthy cells, some cancer cells can 
initially avoid immunosurveillance until sufficient genetic modifications occur through 
mutations and neoantigens are presented on their surface. However, the degree of 
tumor antigen presentation is highly variable among tumors 188, and some tumors can 
evade the immune system by shedding these antigens or making them  
inaccessible 189,190. Furthermore, cancer cells can express membrane proteins and 
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secrete molecules (which include, but are not limited to, programmed death-ligand 1 
(PD-L1), transforming growth factor (TGF)-β, tumor necrosis factor (TNF)-α, colony 
stimulating factor (CSF)-1, interleukin (IL)-1, IL-6, IL-8, and IL-10) in order to attenuate 
the effectiveness of cytotoxic immune cells 191. Secreted chemokines can also shift 
the Th1/Th2 balance by recruiting immune cells such as CD4+CD25+FOXP3+ 
regulatory T-cells and myeloid-derived suppressor cells (MDSC) to help protect the 
tumor from cytotoxic immune cells and promote tumor growth 192–195. This process of 
evading the immune system has emerged as a hallmark of cancer 196.  
Immunotherapy has recently emerged as the fourth pillar of cancer treatment 
and has taken many forms to modulate the immune system to improve response. 
These include cancer vaccines, genetically modified immune cells, and checkpoint 
blockades 191. The last of which has found great success in some forms of cancer, 
even in late-stage metastatic disease, and its pioneers were recently awarded the 
Nobel Prize in Medicine for their efforts 197. The immune system is also involved with 
other types of treatment. Radiotherapy and chemotherapy often result in inflammation 
around the tumor. It is difficult to distinguish between tumor and inflammation with 
conventional imaging, and it is often the cause of apparent pseudoprogression 198.  
The following projects were performed in collaboration with laboratories at MD 
Anderson as part of larger studies. As such, the following data are mostly preliminary 
and either serve as supporting data or the foundation for larger projects. The common 
theme between the projects is the use of NMR spectroscopy to metabolically profile 
immune cells in an effort to distinguish between anti-tumor and pro-tumor activity, 
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monitor treatment response from immunotherapy, and potentially distinguish between 






Metabolic Profiling of Licensed and Unlicensed Natural Killer Cells 
This section is based upon and reproduced with permission from:  
Schafer JR, Salzillo TC, Chakravarti N, Kararoudi MN, Trikha P, Foltz JA, Wang R, Li 
S, Lee DA. Education-dependent activation of glycolysis promotes the cytolytic 
potency of licensed human natural killer cells. Journal of Allergy and Clinical 
Immunology. 2019;143(1):346-358.e6. (License number: 1049029-4) 
Introduction 
NK cells belong to the innate immune system and respond to activated stress 
signals on cells that are affected by infection or malignant transformation 199 by 
producing cytotoxic effects and producing cytokines such as INF-γ to prime other 
immune cells for response 200. NK cells respond to both allogenic and nonallogenic 
cells, and their resultant cytotoxic effect is a result of the balance between activation 
and inhibitory signaling 201. During maturation, in a process known as education 202, 
bone-marrow-derived NK cells which possess inhibitory killer cell Ig-like (KIR) 
receptors (or Ly49 in mice) are “licensed” by major histocompatibility complex (MHC) 
class 1 molecules and have been shown to have enhanced proliferation and mature 
cytotoxic and cytokine production functionality 203. This is also known as the arming 
model. A minority of NK cells which do not possess the inhibitory receptors are 
“unlicensed” and are hyporesponsive and functionally defective in most cases 204. 
Once a NK cell binds to a distressed cell, the NK cell’s functionality is adapted 
based on the presence or absence of MHC class 1 molecules on the bound cell 205. 
Chronic binding between MHC class 1 molecules and KIR receptors on the licensed 
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NK cells allows the NK cells to recognize a bound cell as self and produces inhibitory 
and disarming effects 206. Thus, both unlicensed and licensed NK cells are self-tolerant 
as unlicensed cells are hyporesponsive 207 while licensed cells are eventually inhibited 
after chronic exposure to MHC class 1 molecules 208. In response to cells which are 
absent of MHC class 1 molecules, licensed NK cells can mount an unattenuated 
cytotoxic and cytokine production effector response, while unlicensed cells still remain 
hyporesponsive 202. It is hypothesized that alternate methods of NK cell education 
exist, and that unlicensed NK cells can become activated unconventionally 209,210. 
Furthermore, while uneducated NK cells are characterized by hyporesponse and 
higher threshold for activity, their lack of inhibitory receptors do give them utility in 
fighting persistent diseases with a high expression of MHC class 1 molecules such as 
some viruses and cancers 211–213. In the tumors that downregulate their MHC class 1 
expression, adoptive therapy with NK cells has shown promise as an effective 
immunotherapy 214–217.  
The goal of this study was to characterize the mechanism of enhanced function 
of licensed NK cells for degranulation and cytokine production in targets expressing 
MHC class 1 molecules 218. Initial experiments using reverse-phase protein array 
showed that several proteins involved in metabolism such as MIF, MTCO2, SDHB, 
and PKM2 were overexpressed in licensed NK cells compared with unlicensed cells. 
Thus, metabolic profiling of licensed and unlicensed NK cells was performed to 




Preparation of the licensed and unlicensed NK cells for metabolic profiling was 
performed according to prior literature 218 and as described by the authors as follows.  
Human Subjects: NK cells were derived from peripheral blood or buffy coats of 
healthy volunteer donors under the MD Anderson Cancer Center IRB-approved 
protocol LAB07-0296 or IRB exemption PA13-0978. 
NK Cell Isolation: NK cells were isolated from whole blood or buffy coats using 
Rosette-Sep (Stem Cell Technologies) density-gradient centrifugation as previously 
described 219.  
KIR and HLA Typing: DNA was isolated from NK cells and submitted to the HLA 
laboratory at the University of Texas MD Anderson Cancer Center for HLA and KIR 
typing. HLA typing was performed at the intermediate-resolution level at HLA-A, HLA-
B, and HLA-C loci by PCR amplification and oligonucleotide hybridization (One 
Lambda). KIR genotyping was performed with reverse sequence-specific 
oligonucleotide methodology using fluorescently labeled beads conjugated to 
oligonucleotide probes (One Lambda). The HLA group for KIR binding was 
determined using the KIR Ligand Calculator maintained by the European 
Bioinformatics Institute of the European Molecular Biology Labs (EMBL-EBI) 
(http://www.ebi.ac.uk/ipd/kir/ligand.html). 
Licensed and Unlicensed NK cell discrimination: To avoid confounding from 
expression of multiple KIRs, here we identified licensed and unlicensed NK cells as 
those expressing a single inhibitory KIR in an individual who has or lacks, respectively, 
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the relevant cognate HLA ligand and lacks a complementary activating KIR (e.g., 
KIR2DL1+KIR2DL2/3−KIR3DL1− NK cells in an HLA-C*0201 individual who lacks the 
KIR2DS1 gene). Licensed status was determined irrespective of NKG2A expression. 
Flow Cytometry: NK cells were labeled with fluorescently conjugated human 
antibodies to determine licensed and unlicensed NK cell populations: CD56 PerCP 
CY5.5 (Biolegend), CD3 APC Cy7 (Biolegend), KIR2DL1 FITC (R&D), KIR2DL2/3 
APC (Miltenyi), and KIR3DL1 PE (Beckman Coulter). Cells were stained with 
antibodies at concentrations according to manufacturer guidelines and titrated when 
necessary. For intracellular staining, cells were washed with staining buffer containing 
phosphate buffered saline (PBS) and 5% fetal bovine serum (FBS). Cells were fixed 
in 2% formaldehyde for 10 minutes, then washed and permeablized with methanol on 
ice for 10 minutes. They were then washed with staining buffer, followed by staining 
for p-38 MAPK (D13E1) antibody (Cell Signaling Technologies). Flow cytometry was 
performed on an LSR Fortessa (BD Biosciences).  
Cell Sorting: Cells were labeled with the following fluorescently conjugated human 
antibodies: CD56 PerCP CY5.5 (Biolegend), CD3 APC Cy7 (Biolegend), KIR2DL1 
FITC (R&D), KIR2DL2/3 APC (Miltenyi), and KIR3DL1 PE (Beckman Coulter). Cells 
were stained with antibodies at concentrations according to manufacturer guidelines 
and titrated when necessary. Cells were sorted using a FACSAria IIu sorter (BD 
Biosciences).  
Cell Expansion: To generate sufficient numbers of unlicensed NK cells for phenotypic 
and metabolic studies, freshly isolated or flow-sorted single-KIR+ NK cells were 
expanded by stimulation with K562 Clone9.mbIL21 feeder cells for 14–21 days as 
96 
  
previously described 220. Briefly, irradiated K562 Clone9.mbIL21 feeder cells were 
added to the NK cell culture conditions at a ratio of 2:1 at day 1 and 1:1 at days 7 and 
14.  
Cell Culture: Mononuclear cells from peripheral blood were cultured in RPMI 1640 
Medium supplemented with 50 IU/mL recombinant human IL-2, 10% FBS, L-
glutamine, and penicillin/streptomycin, as previously described 220. The medium was 
changed every other day. 
Sample Preparation for Metabolic Profiling: 10 million cells were spun down into 
pellets and frozen on dry ice for metabolic profiling. Extraction of water-soluble 
metabolites is the same procedure as described in GENERAL METHODS (Chapter 
2) except that because cells were used instead of tissue, the pulverizing and weighting 
steps were skipped, and the cell pellets were immediately lysed and vortexed in the 
methanol-water solution. All other procedures for metabolite extraction, NMR 
spectroscopy, and metabolite pool size measurements were followed as described in 
GENERAL METHODS.  
Statistical Analysis of Ex Vivo Metabolite Pool Size Measurements: Metabolite 
pool sizes in units of µM per 10 million cells were calculated in N = 4 licensed and N 
= 4 unlicensed samples. Statistical significance was determined between the two 
groups using unpaired two-tailed T-tests for each identified metabolite. Significance 
was attributed to comparisons that produced p < 0.05.   
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Results and Discussion 
In licensed NK cells, the pool sizes of glutamate, aspartate, and taurine were 
significantly decreased compared with unlicensed NK cells (Fig. 5.1). This was 
accompanied by non-significant increases in acetate and lactate in licensed NK cells 
compared with unlicensed cells. Both glutamate and aspartate can be catabolized into 
the TCA cycle to provide substrates for oxidative phosphorylation 221. Additionally, 
taurine is an antioxidant which is beneficial to quench the excess reactive oxygen 
species produced from oxidative phosphorylation 222.  
Additional experiments in this study, which were performed by Jolie R. Schafer, 
who is the first-author of this manuscript, demonstrated from Seahorse assays that 
licensed NK cells possessed a significantly higher extracellular acidification rate 
(ECAR) compared with unlicensed cells, and thus higher rates of glycolysis and 
glycolytic capacity. Oxygen consumption rate (OCR) was similar between the two NK 
cell types, which suggests that mitochondrial respiration through oxidative 
phosphorylation was unchanged.  
Metabolic inhibition with the glycolytic inhibitor, 2-DG, did not reduce cytotoxic 
potential for either NK cell type. Licensed NK cell cytotoxicity was only significantly 
reduced when 2-DG administration was combined with glucose starvation. When the 
oxidative phosphorylation inhibitor, oligomycin, was administered, unlicensed NK cell 
cytotoxicity was drastically reduced whereas licensed NK cell cytotoxicity was only 
modestly affected.  
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Taken collectively, it was postulated that licensed NK cells utilized both 
glycolysis and oxidative phosphorylation during activation whereas unlicensed cells 
primarily relied on oxidative phosphorylation. This increase in glycolysis and rapid 
generation of ATP could be instrumental in cytotoxic activities in licensed NK cells.  
 
 
Figure 5.1: Metabolic profiling of licensed and unlicensed natural killer cells. Licensed 
and unlicensed NK cell samples were metabolically profiled using NMR spectroscopy, 
and the above metabolites were identified and quantified. Error bars represent 
standard deviation. Average metabolite concentration between the two groups was 
tested for significance using unpaired two-tailed T-tests for each identified metabolite. 
Significance was attributed to comparisons that produced p < 0.05. * p < 0.05.   
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Metabolic Profiling of CD14+ Monocytes and Polarized Macrophages 
Introduction 
Monocytes are leukocytes that are produced in the bone marrow and released 
into the bloodstream. They eventually migrate into different tissues and differentiate 
into macrophages, dendritic cells, and osteoclasts 223. Monocytes are often divided 
into two established subsets. Monocytes with CD14hiCD16- expression are known as 
classic monocytes, express CCR2 chemokine receptors, and are recruited to areas of 
inflammation. The other, CD14+CD16+ monocytes, share a similar phenotype as 
mature tissue-resident macrophages and express CCR5 chemokine receptors 224.  
Circulating monocytes can be recruited to different tissues to replenish the tissue-
resident macrophage population (such as alveolar space in lungs, central nervous 
system, and spleen). In the central nervous system, the majority of myeloid cells are 
microglia and macrophages derived from peripheral blood monocytes 225.  
Monocytes are also recruited to areas of inflammation where they differentiate 
into macrophages. These macrophages can be activated into different states 
depending on surrounding stimulating factors and possess distinct properties in 
regards to morphology, cell surface markers, and cytokine production 225. The 
classically-activated state (M1) is proinflammatory and is stimulated by IFN-γ and 
lipopolysaccharide (LPS) 226. The alternatively-activated state (M2) is associated with 
tissue repair and increased mannose-receptor activity and is induced by IL-4 and IL-
13 227,228. M2 macrophages have also been implicated in the remodeling of the 
extracellular matrix and angiogenesis 229,230. Therefore, it is hypothesized that tumor-
associated macrophages (TAM) represent the M2 phenotype and help cultivate a 
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tumor-promoting and immunosuppressive microenvironment 231–233. It has also been 
suggested that TAM are heterogeneous and are comprised of primarily M1 
macrophages state in early-stage tumors whereas M2 phenotypes are dominant in 
late-stage and hypoxic tumors 181,234. In GBM, M2 TAM represent the majority of 
immune-infiltrating cells 195. It is still under debate whether macrophages belong to 
only one of the discrete states or reside in a spectrum of states with variable 
expression of the different phenotypes. Furthermore, it is not determined whether 
macrophages permanently differentiate into one of the states or if there is plasticity 
between them 223,235.   
The purpose of this study was to elucidate metabolic differences between 
peripheral blood and tissue-residing CD14+ monocytes from GBM patients and 
healthy volunteers. In addition, the metabolic profiles of unpolarized (M0), M1, and M2 
macrophages were investigated. The goal was to append this data to a larger set of 
experiments to potentially identify a metabolic mechanism for macrophage activation 





Human Subjects: This study was conducted under protocols LAB03-0687 and 
LAB06-0008, which were approved by the Institutional Review Board of The University 
of Texas MD Anderson Cancer Center. The Research Ethics Board of McGill 
University approved the use of nonidentifiable tissues for research. Patient tumors 
were graded pathologically as newly diagnosed adult glioblastoma (N = 3) by a 
neuropathologist according to the World Health Organization classification. At least 2 
g of viable, nonnecrotic tumor was required to obtain sufficient quantities of immune 
cells for analysis and was processed within 1 hour after resection. Peripheral blood 
was drawn from the patients intra-operatively and from healthy donors. Control 
CD14+ cells (general marker of myeloid lineage cells) (N = 3) were derived from tissue 
samples surgically resected from nonmalignant cases of intractable epilepsy 
(Montreal Neurological Institute). These samples were obtained from tissues removed 
during the approach to the lesion site. Human glioblastoma or nonmalignant central 
nervous system tissue was digested with Liberase TM Research Grade Enzyme 
(Roche Diagnostics). After enzymatic digestion, myelin was removed by centrifugation 
in a Percoll gradient. 
Isolation of Myeloid Cells from Fresh Human Glioblastoma Tissue: Freshly 
resected human glioblastoma tissue was minced into small pieces using a scalpel, 
dissociated using a Pasteur pipette, and suspended in Roswell Park Memorial Institute 
(RPMI) 1640 medium with L-glutamine (Mediatech Inc.) containing Liberase TM 
Research Grade Enzyme at a final concentration of 30 μg/mL. The prepared mixture 
was incubated for 1 h at 37°C with agitation. After brief centrifugation, the pellet was 
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resuspended in 20 mL of 1.03 Percoll underlaid with 10 mL of 1.095 Percoll and 
overlaid with 10 mL of fluorescence-activated cell sorter buffer (5% FBS, 
MilliporeSigma) in PBS (Mediatech Inc.). The tube was centrifuged at 1,200 g for 20 
min at room temperature with no brake. After centrifugation, the cell layer on top of 
the 1.095 Percoll was collected, filtered through a 70-μm nylon strainer (BD 
Biosciences), washed, stained with Trypan blue dye (MilliporeSigma), and counted in 
a Neubauer chamber (Fisher Scientific). Afterward, myeloid cells were blocked for 
nonspecific binding using FcγR-binding inhibitor (Miltenyi Biotec) and magnetically 
labeled with CD14 microbeads (Miltenyi Biotec) at 4° C for 30 min. The cell suspension 
was loaded onto a MACS Column (Miltenyi Biotec) in the magnetic field. The negative 
fraction was discharged. Upon removal of the column from the MACS separation 
system, CD14+ cells were eluted as positive fractions. 
Isolation of Microglia from Human Nontumoral Tissue: Samples of brain tissue 
surgically resected from cases of intractable epilepsy of nonmalignant origin were 
processed as described previously 225, and microglia were separated magnetically 
with CD14 microbeads. 
Isolation of CD14+ Monocytes: Peripheral blood mononuclear cells (PBMCs) were 
purified from 3 healthy blood donors (Gulf Coast Blood Center, Houston, Texas), 3 
healthy donors (volunteers), and from 3 glioblastoma patients undergoing resection at 
The University of Texas MD Anderson Cancer Center by centrifugation on a Ficoll-
Hypaque density gradient (MilliporeSigma) 236. CD14+ monocytes were isolated from 




Monocyte Differentiation into the M0, M1, M2A, or M2C Phenotype: Monocytes 
were cultured in RPMI 1640 medium containing L-glutamine (Mediatech Inc.), 20% 
heat-inactivated FBS (MilliporeSigma) without penicillin and streptomycin. 
Nonpolarized M0 macrophages were generated by culturing monocytes in medium 
with granulocyte-macrophage colony-stimulating factor (GM-CSF; 50 ng/mL) and 
harvested on day 4. M1 and M2 macrophages were cultured in medium with GM-CSF 
(50 ng/mL) and macrophage colony-stimulating factor (M-CSF; 100 ng/mL), 
respectively.  On day 4, 50% of complete, fresh M1 or M2 monocyte medium was 
added for 48 h. Further polarization was achieved by removing the medium and 
culturing cells for additional 48 h in fresh medium with GM-CSF (50 ng/mL), 
lipopolysaccharide from Escherichia coli 055:B5 (100 ng/mL; MilliporeSigma), IFN-γ 
(50 ng/mL; Peprotech), and TNF-α (20 ng/mL; Peprotech) for M1 polarization; M-CSF 
(100 ng/mL) and IL-4 (20 ng/mL; R&D Systems) for M2A polarization; M-CSF (100 
ng/mL), IL-10 (10 ng/mL; Peprotech) and TGF-β1 (10 ng/mL; Peprotech) for M2C 
polarization. On day 8, M1, M2a, and M2c macrophages were harvested.  
Sample Preparation for Metabolic Profiling: 10 million cells were spun down into 
pellets and frozen on dry ice for metabolic profiling. Extraction of water-soluble 
metabolites is the same procedure as described in GENERAL METHODS (Chapter 
2) except that because cells were used instead of tissue, the pulverizing and weighting 
steps were skipped, and the cell pellets were immediately lysed and vortexed in the 
methanol-water solution. All other procedures for metabolite extraction, NMR 
spectroscopy, and metabolite pool size measurements were followed as described in 
GENERAL METHODS.  
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Statistical Analysis of Ex Vivo Metabolite Pool Size Measurements: Metabolite 
pool sizes in units of µM per 10 million cells were calculated in each of the N = 3 
CD14+ monocytes and polarized macrophage cell samples. Statistical significance for 
each metabolite was determined using ordinary one-way ANOVA and follow-up 
Fisher’s Least Significant Difference tests. Due to the large number of comparisons 
(each set of comparisons made for 24 metabolites), the false discovery rate was 
controlled using the two-stage step-up method of Benjamini, Krieger and Yekutieli (Q 





Results and Discussion 
33 metabolites were identified which appeared in at least one of the NMR 
spectra. After disqualifying the metabolites which were present in only a sparse 
number of samples or whose resonances were consistently convolved with other 
metabolite peaks, there were 24 metabolites considered for quantification and 
statistical analysis. The group of metabolites consists of several amino acids, lipids, 
and carbohydrates.  
The metabolomic profiles of CD14+ blood cells isolated from glioblastoma 
patients and healthy blood donors, and CD14+ cells isolated from freshly resected 
glioblastoma tissue or nonmalignant surgical samples were examined. The analysis 
revealed concentrations of 3 metabolites reached statistical significance. Acetate, 
propionate, and formate were all elevated in blood- and tissue-derived CD14+ cells 
from GBM patients compared to those from healthy donors (Fig. 5.2). 
The metabolomic profiles of nonpolarized (M0), classically-activated (M1), and 
alternatively-activated (M2A, M2C) macrophages were investigated. Five metabolites 
reached statistical significance (Fig. 5.3). Acetate had markedly higher concentration 
in M0, M2A, and M2C macrophages than M1 macrophages. Glutamate was elevated 
in M2A macrophages compared to other groups. Increased glutamate could be the 
result of upregulated arginine-to-ornithine conversion which occurs in M2 
macrophages 237–239. In contrast, M1 macrophages utilize most of their arginine in 
cytotoxic NOS production.  Taurine was downregulated in M0 macrophages compared 
to the other groups and was elevated in M2A macrophages compared to M1 and M2C 
groups. Lactate was upregulated in M2A and M2C macrophages compared to M0 
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macrophages which could be a result of increased glycolysis in these subtypes. 
Formate was elevated in M0 macrophages compared to the other groups.  
These data elucidate only one dimension of the metabolism of tumor-
associated monocytes and the mechanism behind macrophage polarization and 
should be combined with genotyping or protein expression data to perform an 
integrated pathway analysis to look deeper into these processes. Furthermore, 
phantoms containing these cells could be scanned on an MR spectrometer to test the 
feasibility of using clinical 1H MRS to detect monocyte involvement and macrophage 
polarization. However, advanced pulse sequences such as spectral editing and 
efficient fat/water suppression would most likely be required to detect the subtle 






Figure 5.2: Significantly altered metabolites in CD14+ monocytes residing in blood (-
B) and tissue (-T) samples from healthy donors (HD) and GBM patients. Error bars 
represent standard deviation. Statistical significance was determined using ordinary 
one-way ANOVA and follow-up Fisher’s Least Significant Difference tests. The false 
discovery rate was controlled using the two-stage step-up method of Benjamini, 
Krieger and Yekutieli, and significance was attributed to comparisons that produced  







Figure 5.3: Significantly altered metabolites in unpolarized (M0), classically activated 
(M1) and alternatively activated (M2A, M2C) macrophages. Error bars represent 
standard deviation. Statistical significance was determined using ordinary one-way 
ANOVA and follow-up Fisher’s Least Significant Difference tests. The false discovery 
rate was controlled using the two-stage step-up method of Benjamini, Krieger and 
Yekutieli, and significance was attributed to comparisons that produced q < 0.05.  





Several aspects of brain tumor metabolism and immunometabolism were 
investigated and discussed. With regards to the main body of work discussed in 
CHAPTER 4, this is the most comprehensive longitudinal study using hyperpolarized 
MR to probe tumor metabolism to my knowledge. Not only were data acquired from 
several time-points which spanned the entirety of tumor progression (development, 
regression, and recurrence), they were acquired using multiple modalities (anatomic 
MRI, hyperpolarized MRS, NMR spectroscopy, and immunohistochemistry) which 
evaluated orthogonal aspects of tumor progression (anatomic growth, real-time 
metabolic conversion, steady-state metabolite pool size, and protein expression). 
Because each class of data were acquired at the same time-points, the individual 
evolution as well as the interrelationship of the variables could be studied. The main 
purpose of this work was to highlight the capabilities of the novel imaging technique 
of hyperpolarized MR which can measure real-time metabolic activity in vivo. The use 
of this technology to measure hyperpolarized pyruvate-to-lactate conversion is 
currently in clinical trials, and this project demonstrated the value that it could add to 
routine imaging of cancer by addressing several clinical challenges (predicting 
aggressive expansion of tumors during development, distinguishing between true 
progression and pseudoprogression following treatment, predicting treatment 
outcomes, quantifying treatment response, and predicting tumor relapse). Therefore, 
there are both clinical and scientific implications of this study.  
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An improvement in this study would be to implement a more aggressive 
treatment regimen to induce a greater reduction in tumor burden. This could be in the 
form of increased dose of radiotherapy- either whole-brain or targeted with 3-D 
planning or intensity-modulated to reduce toxicity- or with adjuvant chemo-,  
targeted-, or immunotherapy. Doing so would increase the magnitude of tumor volume 
and metabolic changes which could lead to discovery or more nuanced alterations. 
Additionally, the period of remission would be extended which would allow more 
measurements to be acquired and could lead to the diagnosis of transient responses 
such as a gain of treatment resistance. Each of these aspects are directions for future 
work. Furthermore, this study would benefit from a similar analysis with another GBM 
line such as a different GSC mouse model to determine if it is a general pattern among 
brain tumors. Eventually, one could work his/her way back to the goal discussed in 
CHAPTER 3 of trying to predict tumor aggressiveness with hyperpolarized MR which 
would also be of immense value to the clinic. As hyperpolarized MR makes its way 
through clinical trials as a metabolic imaging modality, we believe its value in cancer 
care will continue to grow. Just as PET imaging became a staple in the clinic, so too 
should hyperpolarized MRI as an invaluable tool for interrogating the metabolism of 
cancer.  
Lastly, the concept of immunometabolism was discussed in CHAPTER 5 in the 
context of two projects- one that was part of a larger study for investigating NK cell 
education, and the other that could form the foundation of a new project to probe 
macrophage metabolism. This discussion was primarily to introduce a couple of routes 
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that metabolic profiling could be applied to immunology and highlight the work I 
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